1
|
Bastard JP, Dridi-Brahimi I, Vatier C, Fellahi S, Fève B. Biological markers of adipose tissue: Adipokines. Ann Endocrinol (Paris) 2024:S0003-4266(24)00050-7. [PMID: 38614158 DOI: 10.1016/j.ando.2024.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/15/2024]
Abstract
We currently have a large sum of clinical and experimental data documenting the involvement of numerous adipokines in the maintenance of energy homeostasis in healthy individuals and their dysregulation in diseases such as obesity, metabolic syndrome or type 2 diabetes. Despite the impressive discoveries made in this field over many years, much remains to be done before understanding all the physiological and pathological implications, and hoping for the development of other effective and safe therapeutic strategies. Two original adipokines will be taken as examples to illustrate these remarks, chemerin and neuregulin 4.
Collapse
Affiliation(s)
- Jean-Philippe Bastard
- Département de biochimie-pharmacologie, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Henri-Mondor, Créteil, France; FHU-SENEC, Inserm U955 and université Paris Est (UPEC), UMR U955, faculté de santé, Créteil, France.
| | - Imane Dridi-Brahimi
- Département de biochimie-pharmacologie, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Henri-Mondor, Créteil, France
| | - Camille Vatier
- Sorbonne université-Inserm, centre de recherche Saint-Antoine UMR S_938, 75012 Paris, France; Institut hospitalo-universitaire de cardio-métabolisme et nutrition (ICAN), Paris, France; Service d'endocrinologie-diabétologie, centre de référence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité (PRISIS), hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 75012 Paris, France
| | - Soraya Fellahi
- Département de biochimie-pharmacologie, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Henri-Mondor, Créteil, France; Sorbonne université-Inserm, centre de recherche Saint-Antoine UMR S_938, 75012 Paris, France; Institut hospitalo-universitaire de cardio-métabolisme et nutrition (ICAN), Paris, France
| | - Bruno Fève
- Sorbonne université-Inserm, centre de recherche Saint-Antoine UMR S_938, 75012 Paris, France; Institut hospitalo-universitaire de cardio-métabolisme et nutrition (ICAN), Paris, France; Service d'endocrinologie-diabétologie, centre de référence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité (PRISIS), hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 75012 Paris, France
| |
Collapse
|
2
|
Zaroui A, Kharoubi M, Gounot R, Oghina S, Degoutte C, Bezard M, Galat A, Guendouz S, Roulin L, Audard V, Leroy V, Teiger E, Poullot E, Molinier-Frenkel V, Le Bras F, Belhadj K, Bastard JP, Fellahi S, Shourick J, Lemonier F, Damy T. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study. ESC Heart Fail 2024. [PMID: 38444090 DOI: 10.1002/ehf2.14671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 12/11/2023] [Accepted: 12/20/2023] [Indexed: 03/07/2024] Open
Abstract
AIMS Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated biomarker levels and limited thresholds for stratifying severe cardiac damage. METHODS AND RESULTS This prospective, observational, cohort study included de novo, confirmed cardiac AL amyloidosis patients at the Henri Mondor National Reference Centre. The goal was to identify predictors of mortality to enhance prognostic stratification and improve informed decision-making regarding therapy. Over the 12-year study period, among the 233 patients included, 133 were NYHA III-IV and 179 Mayo 2004 III. The independent predictors for mortality identified were hsTnT, NT-proBNP, cardiac output, and conjugated bilirubin. A novel prognostic, conditional stratification, Mondor amyloidosis cardiac staging (MACS) was developed with biomarker cut-off values for Stage 1: hsTnT ≤ 107 ng/L and NT-proBNP ≤ 3867 ng/L (n = 77; 33%); for stage 2 NT-proBNP > 3867 ng/L (n = 72; 30%). For stage 3, if troponin >107 ng/L, regardless of NT-proBNP then CB 4 μmol/L, was added (n = 41; 17.5%) and stage 4: CB > 4 μmol/L (n = 43; 18.5%). The median overall survival was 8 months 95% CI [2-24]. At 1 year, 102 (44%) patients died and the Kaplan-Meier median survival with MACS Stage 1 was not reached, while stage 2 was 15.2 months (95% CI [11-18]) and stage 3, 6.6 months (95% CI [1-13]). Notably, among European stage II patients, 17.1%, n = 8 were MACS stage 3 and European stage IIIb 21.4% (n = 23) were MACS stage 4. Importantly, among European stage IIIb patients 42.2% (n = 29) were classified MACS stage 4 and 12.5% n = 9 were only MACS stage 2. CONCLUSIONS The Mondor prognostic staging system, including conjugate bilirubin may significantly improve prognostic stratification for patients with severe cardiac amyloidosis.
Collapse
Affiliation(s)
- Amira Zaroui
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
- Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health, Creteil, France
| | - Mounira Kharoubi
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
- Univ Paris Est Créteil (UPEC), National Institute of Medical Research (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
| | - Romain Gounot
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Lymphoid Malignancies Unit, Henri Mondor Teaching Hospital, Creteil, France
| | - Silvia Oghina
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
| | - Charlotte Degoutte
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Lymphoid Malignancies Unit, Henri Mondor Teaching Hospital, Creteil, France
| | - Melanie Bezard
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
- Univ Paris Est Créteil (UPEC), National Institute of Medical Research (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
| | - Arnault Galat
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
| | - Soulef Guendouz
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
| | - Louise Roulin
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Univ Paris Est Créteil (UPEC), National Institute of Medical Research (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
- Lymphoid Malignancies Unit, Henri Mondor Teaching Hospital, Creteil, France
| | - Vincent Audard
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Assistance Publique des Hôpitaux de Paris (AP-HP), Nephrology and Renal Transplantation Department, Henri Mondor Teaching Hospital, Rare Disease Reference Centre for Idiopathic Nephrotique Syndrome, University Hospital Federation for Innovative Therapy for Immune Disorders, Créteil, France
- Department of Epidemiology, Toulouse Teaching Hospital, Toulouse, France
| | - Vincent Leroy
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Hepatology, Henri Mondor Teaching Hospital, Creteil, France
| | - Emmanuel Teiger
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
- Univ Paris Est Créteil (UPEC), National Institute of Medical Research (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
| | - Elsa Poullot
- Department of Pathology, Henri Mondor Teaching Hospital, Creteil, France
| | - Valérie Molinier-Frenkel
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Immunology, LBMR Immunoglobulin deposit diseases and amyloses, France Henri Mondor Teaching Hospital, Creteil, France
| | - Fabien Le Bras
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Lymphoid Malignancies Unit, Henri Mondor Teaching Hospital, Creteil, France
| | - Karim Belhadj
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Lymphoid Malignancies Unit, Henri Mondor Teaching Hospital, Creteil, France
| | | | - Soraya Fellahi
- Biochemistry Department Henri Mondor Teaching Hospital, Creteil, France
| | - Jason Shourick
- Department of Epidemiology, Toulouse Teaching Hospital, Toulouse, France
| | - Francois Lemonier
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Univ Paris Est Créteil (UPEC), National Institute of Medical Research (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
- Lymphoid Malignancies Unit, Henri Mondor Teaching Hospital, Creteil, France
| | - Thibaud Damy
- French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU A-TVB, Henri Mondor Teaching Hospital, APHP, Creteil, France
- Department of Cardiology, Henri Mondor Teaching Hospital, Creteil, France
- Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health, Creteil, France
| |
Collapse
|
3
|
Bastard L, Rech JS, Senet P, Soria A, Fellahi S, Vatier C, Georgin-Lavialle S, Bastard JP. Does adipose tissue contribute to acute infection-related inflammation in COVID-19? Nutr Metab Cardiovasc Dis 2023; 33:2527-2528. [PMID: 37788947 DOI: 10.1016/j.numecd.2023.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 06/22/2023] [Accepted: 07/17/2023] [Indexed: 10/05/2023]
Affiliation(s)
- Léa Bastard
- Service de Médecine interne, Hôpital Tenon, Paris, France
| | | | - Patricia Senet
- Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France
| | - Angèle Soria
- Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France
| | - Soraya Fellahi
- Sorbonne Université-Inserm, Centre de Recherche Saint-Antoine UMR S_938, 75012 Paris, France; Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de biochimie-pharmacologie-biologie moléculaire-génétique médicale, Créteil, France
| | - Camille Vatier
- Sorbonne Université-Inserm, Centre de Recherche Saint-Antoine UMR S_938, 75012 Paris, France; Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris, France; Assistance Publique- Hôpitaux de Paris -Hôpital Saint-Antoine, Service d'Endocrinologie-Diabétologie, Centre de Référence des Maladies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité (PRISIS), 75012 Paris, France
| | - Sophie Georgin-Lavialle
- Service de Médecine interne, Hôpital Tenon, Paris, France; Sorbonne Université-Inserm, Centre national de référence des maladies auto inflammatoires et de l'amylose AA (CEREMAIA), Hôpital Tenon, Paris, France
| | - Jean-Philippe Bastard
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de biochimie-pharmacologie-biologie moléculaire-génétique médicale, Créteil, France; FHU-SENEC, INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de Santé, Créteil, France.
| |
Collapse
|
4
|
Serrano E, Bastard JP, Trystram L, Fellahi S, Soula HA, Thenet S, Oppert JM, Clément K, Poitou C, Genser L. Serum Versus Fecal Calprotectin Levels in Patients with Severe Obesity Before and 6 Months After Roux-Y-Gastric Bypass: Report of the Prospective Leaky-Gut Study. Obes Surg 2023; 33:4017-4025. [PMID: 37924465 DOI: 10.1007/s11695-023-06911-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 10/13/2023] [Accepted: 10/18/2023] [Indexed: 11/06/2023]
Abstract
INTRODUCTION Obesity is associated with low-grade inflammation, including intestinal inflammation based on fecal or serum calprotectin (FC-SC) measurement. Roux-en-Y gastric bypass (RYGB) improves obesity-related parameters. However, the association between FC-SC levels and postoperative course and the link with metabolic and inflammatory phenotypes before and after RYGB remains unclear. METHODS We determined SC levels in 48 patients before (T0) and 6 months after (T6M) RYGB. We then analyzed postoperative changes in FC-SC levels and the relationship with inflammation and metabolic status. RESULTS Twenty-three patients (48%) had elevated SC levels (˃2.9 μg/mL) at T0 and T6M. Six of 29 patients (20.7%) had elevated FC concentrations (>50 μg/g) at T0 vs. 16 of 17 patients (94.1%) at T6M (p=0.006). At T0, FC levels correlated with BMI (Rho=0.63; p=0.001) and systemic inflammation (CRP: Rho=0.66, p=0.0006; IL-6: Rho=0.48, p=0.03; haptoglobin: Rho=0.75; p= 0.0006). SC tended to be positively associated with triglyceride levels (Rho=0.34; p=0.08), BMI (Rho=0.34; p=0.08), and inflammatory markers (CRP: Rho=0.33; p=0.09; IL-6: Rho=0.36; p=0.06). FC levels were associated with increased jejunal IL-17+CD8+ T-cell densities (Rho:0.90; p=0.0002). FC and SC were correlated together at T0 (Rho=0.83; p<0.001) but not at T6M. At T6M, SC decreased by 53.6%, whereas FC increased by 79.7%. SC and FC were not associated with any of the variables studied at T6M. CONCLUSION FC is a surrogate marker of systemic and intestinal inflammation and adiposity, whereas SC only tends to correlate with systemic inflammation. At 6 months after RYGB, SC-based systemic inflammation decreased, whereas FC-based intestinal inflammation increased. FC and SC levels follow different trajectories and are unrelated to improvements following bariatric surgery.
Collapse
Affiliation(s)
- Ella Serrano
- Sorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches, NutriOmics, research unit, 91 boulevard de l'hôpital, Paris, France
| | - Jean-Philippe Bastard
- Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Créteil, France
- FHU-SENEC, INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de Santé, Créteil, France
| | - Laurence Trystram
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Functional Coprology, Paris, France
| | - Soraya Fellahi
- Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Hedi A Soula
- Sorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches, NutriOmics, research unit, 91 boulevard de l'hôpital, Paris, France
| | - Sophie Thenet
- Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, EPHE, PSL University, F-75012, F-75014, Paris, France
| | - Jean-Michel Oppert
- Sorbonne Université, Department of Nutrition, Assistance Publique- Hôpitaux de Paris, AP-HP, Pitié Salpêtrière University Hospital, 75013, Paris, France
| | - Karine Clément
- Sorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches, NutriOmics, research unit, 91 boulevard de l'hôpital, Paris, France
- Sorbonne Université, Department of Nutrition, Assistance Publique- Hôpitaux de Paris, AP-HP, Pitié Salpêtrière University Hospital, 75013, Paris, France
| | - Christine Poitou
- Sorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches, NutriOmics, research unit, 91 boulevard de l'hôpital, Paris, France
- Sorbonne Université, Department of Nutrition, Assistance Publique- Hôpitaux de Paris, AP-HP, Pitié Salpêtrière University Hospital, 75013, Paris, France
| | - Laurent Genser
- Sorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches, NutriOmics, research unit, 91 boulevard de l'hôpital, Paris, France.
- Sorbonne Université, Department of Hepato-Biliary and Pancreatic Surgery, Assistance Publique- Hôpitaux de Paris, AP-HP, Pitié-Salpêtrière University Hospital, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| |
Collapse
|
5
|
Adam-Hassan F, Dridi-Brahimi I, Vatier C, Bastard JP. Are there relevant thresholds of insulin-independent indices across the lifespan to predict alterations in glycemic control? Lancet Reg Health Eur 2023; 33:100728. [PMID: 37693689 PMCID: PMC10482732 DOI: 10.1016/j.lanepe.2023.100728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 08/21/2023] [Indexed: 09/12/2023]
Affiliation(s)
- Fatimé Adam-Hassan
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Créteil, France
| | - Imane Dridi-Brahimi
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Créteil, France
| | - Camille Vatier
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Service d’Endocrinologie-Diabétologie, Centre de Référence des Maladies Rares de l’Insulino-Sécrétion et de l’Insulino-Sensibilité (PRISIS), Paris 75012, France
- Sorbonne Université-Inserm, Centre de Recherche Saint-Antoine UMR S_938, Paris 75012, France
- Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris, France
| | - Jean-Philippe Bastard
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Créteil, France
- FHU-SENEC, INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de Santé, Créteil, France
| |
Collapse
|
6
|
Fellahi S, Mouri N, Giraud B, Martino S, de Luna G, Sakka M, Joly P, Bastard JP, Galacteros F, Moutereau S. [Impact of voxelotor on hemoglobin electrophoretic and chromatographic profiles]. Ann Biol Clin (Paris) 2023; 81:320-326. [PMID: 37475172 DOI: 10.1684/abc.2023.1814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/22/2023]
Abstract
Voxelotor (GBT440, OXBRYTA®) appeared recently as one of the possible treatments for sickle cell disease. This molecule, by binding the alpha globin of hemoglobin, causes hyperaffinity of the latter for oxygen and reduces its polymerization properties. Several therapeutic trials have been able to show its effectiveness on certain aspects of sickle cell disease; thus, the french HAS (High Authority of Health) college issued an early access authorization and, since 2021, this treatment can be offered to patients under a temporary authorization for use. Consequently, the laboratories that carry out the biological monitoring of sickle cell patients will be confronted with new profiles characteristic of the presence of hemoglobin combined with GBT440. This work presents a collection of images obtained by different techniques: HPLC, capillary electrophoresis, isoelectrofocusing, alkaline gel and acid agar gel electrophoresis in transfused or non-transfused sickle cell disease patients. The ability to observe the presence of GBT440 by these analyzes could be useful in order to characterize the therapeutic follow-up of patients.
Collapse
Affiliation(s)
- Soraya Fellahi
- Département de Biochimie-Biologie Moléculaire-Pharmacologie-Génétique Médicale. Hôpital Universitaire Henri Mondor (AP-HP), 1, rue Gustave Eiffel, 94000 Créteil, France, Sorbonne Université, Inserm UMR_S 938, Centre de recherche Saint-Antoine, Institut hospitalo-universitaire de cardio-métabolisme et nutrition (ICAN), Paris, France
| | - Nadir Mouri
- Département de Biochimie-Biologie Moléculaire-Pharmacologie-Génétique Médicale. Hôpital Universitaire Henri Mondor (AP-HP), 1, rue Gustave Eiffel, 94000 Créteil, France
| | - Baptiste Giraud
- Département de Biochimie-Biologie Moléculaire-Pharmacologie-Génétique Médicale. Hôpital Universitaire Henri Mondor (AP-HP), 1, rue Gustave Eiffel, 94000 Créteil, France
| | - Suella Martino
- Unité des Maladies Génétiques du Globule Rouge, Hôpital Universitaire Henri Mondor (AP-HP), Créteil, France, Inserm U955-IMRB, Equipe Pirenne, Université Paris Est Créteil, Créteil, France
| | - Gonzalo de Luna
- Unité des Maladies Génétiques du Globule Rouge, Hôpital Universitaire Henri Mondor (AP-HP), Créteil, France, Inserm U955-IMRB, Equipe Pirenne, Université Paris Est Créteil, Créteil, France
| | - Mehdi Sakka
- Département de Biochimie Métabolique, Sorbonne Université, Hôpital Pitié-Salpêtrière, (AP-HP), Paris, France
| | - Philippe Joly
- Service de biochimie et de biologie moléculaire Grand Est, Hospices Civils de Lyon, Lyon, France
| | - Jean-Philippe Bastard
- Département de Biochimie-Biologie Moléculaire-Pharmacologie-Génétique Médicale. Hôpital Universitaire Henri Mondor (AP-HP), 1, rue Gustave Eiffel, 94000 Créteil, France
| | - Frédéric Galacteros
- Unité des Maladies Génétiques du Globule Rouge, Hôpital Universitaire Henri Mondor (AP-HP), Créteil, France, Inserm U955-IMRB, Equipe Pirenne, Université Paris Est Créteil, Créteil, France
| | - Stéphane Moutereau
- Département de Biochimie-Biologie Moléculaire-Pharmacologie-Génétique Médicale. Hôpital Universitaire Henri Mondor (AP-HP), 1, rue Gustave Eiffel, 94000 Créteil, France, Inserm U955-IMRB, Equipe Pirenne, Université Paris Est Créteil, Créteil, France
| |
Collapse
|
7
|
Pourcher V, Capeau J, Dudoit Y, Boccara F, Soulié C, Ndoadoumgue AL, Charlotte F, Fellahi S, Bastard JP, Béréziat V, Lagathu C, Marcelin AG, Peytavin G, Boutron-Ruault MC, Tubbax C, D'Avout D'Auerstaedt A, Valantin MA, Schneider L, Costagliola D, Katlama C, Assoumou L, Pourcher G. Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study. J Acquir Immune Defic Syndr 2022; 90:240-248. [PMID: 35185138 DOI: 10.1097/qai.0000000000002939] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Accepted: 01/10/2022] [Indexed: 11/27/2022]
Abstract
OBJECTIVE The aim of this study was to compare clinical characteristics and adipose/liver tissue histology analysis in HIV-infected and HIV-uninfected subjects undergoing bariatric surgery. DESIGN This was a cross-sectional study of HIV-infected subjects undergoing single-port sleeve gastrectomy with prospective enrolment and frequency age (±5 years), sex, and body mass index (BMI, ± 5 kg/m2) matched on HIV-uninfected subjects. METHODS This study was conducted at a single clinical site at Pitié-Salpêtrière hospital-Paris-France comprising 19 HIV-uninfected and 21 HIV-infected subjects with plasma VL < 20 copies/mL, all with a BMI > 40 kg/m2 or >35 kg/m2 with comorbidities. Histology of subcutaneous and visceral abdominal adipose tissue (SCAT/VAT) and liver biopsies was collected during single-port sleeve gastrectomy. Outcomes included anthropometric characteristics, comorbidities, cardiovascular parameters, adipose tissue, and liver histology. RESULTS The age of HIV-infected participants was (median, interquartile range IQR) 48 y (42-51), with 76.2% females, a BMI of 41.4 kg/m2 (37.3-44.4), an antiretroviral duration of 16 y (8-21), current integrase strand transfer inhibitor (INSTI)-based regimen in 15 participants and non-INSTI regimen in 6 participants, and a CD4 count of 864/mm3 (560-1066). The age of controls was 43 y (37-51), with 78.9% females and a BMI of 39.2 kg/m2 (36.3-42.6). Anthropometric characteristics, comorbidities, and cardiovascular parameters did not differ according to HIV status and INSTI treatment. The number of macrophage crown-like structures in SCAT was lower in INSTI-treated participants than in HIV-uninfected participants (P = 0.02) and non-INSTI-treated HIV-infected subjects (P = 0.07). Hepatic steatosis and liver disease severity global score were lower in INSTI-treated participants than in non-INSTI-treated HIV-infected participants (P = 0.05 and P = 0.04, respectively). CONCLUSIONS HIV-infected and HIV-uninfected subjects undergoing bariatric surgery presented a similar profile regarding anthropometric measures, cardiovascular parameters, and comorbidities. However, INSTI-treated participants presented milder SCAT and liver alterations than non-INSTI-treated participants.
Collapse
Affiliation(s)
- V Pourcher
- Sorbonne Université, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - J Capeau
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), RHU CARMMA, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Y Dudoit
- Sorbonne Université, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
| | - F Boccara
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), RHU CARMMA, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
- Sorbonne Université, GRC n°22, C MV-Complications Cardiovasculaires et Métaboliques chez les patients vivant avec le Virus de l'immunodéficience humaine, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Saint-Antoine Service de Cardiologie, Paris, France
| | - C Soulié
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
- Laboratoire de Virologie, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - A L Ndoadoumgue
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - F Charlotte
- Service d'anatomie pathologique, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - S Fellahi
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), RHU CARMMA, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
- Department of Biochemistry-Pharmacology-Molecular Biology, APHP, Hôpital Henri-Mondor, Université Paris Est Créteil, France
| | - J P Bastard
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), RHU CARMMA, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
- Department of Biochemistry-Pharmacology-Molecular Biology, APHP, Hôpital Henri-Mondor, Université Paris Est Créteil, France
| | - V Béréziat
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), RHU CARMMA, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - C Lagathu
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), RHU CARMMA, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - A G Marcelin
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
- Laboratoire de Virologie, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - G Peytavin
- APHP, Service de Pharmacologie and Toxicologie, Hôpital Bichat, IAME, Inserm UMR 1137, UF301, Université de Paris, Paris, France
| | - M C Boutron-Ruault
- Sorbonne Université, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
- Obesity Center, Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France; and
| | - C Tubbax
- Obesity Center, Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France; and
| | - A D'Avout D'Auerstaedt
- Obesity Center, Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France; and
| | - M A Valantin
- Sorbonne Université, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - L Schneider
- Sorbonne Université, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - D Costagliola
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - C Katlama
- Sorbonne Université, AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - L Assoumou
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
| | - G Pourcher
- Obesity Center, Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France; and
- Centre de Recherche en Epidémiologie et Santé des Population (CESP), Inserm, Paris-Saclay University, France
| |
Collapse
|
8
|
Arrestier R, Gendreau S, Mokrani D, Bastard JP, Fellahi S, Bagate F, Masi P, d’Humières T, Razazi K, Carteaux G, De Prost N, Audard V, Mekontso-Dessap A. Acute Kidney Injury in Critically-Ill COVID-19 Patients. J Clin Med 2022; 11:jcm11072029. [PMID: 35407639 PMCID: PMC8999255 DOI: 10.3390/jcm11072029] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 03/25/2022] [Accepted: 03/31/2022] [Indexed: 02/04/2023] Open
Abstract
Purpose: Acute kidney injury (AKI) is common in patients with COVID-19, however, its mechanism is still controversial, particularly in ICU settings. Urinary proteinuria profile could be a non-invasive tool of interest to scrutinize the pathophysiological process underlying AKI in COVID-19 patients. Material and Methods: We conducted a retrospective study between March 2020 and April 2020. All patients with laboratory-confirmed COVID-19 and without end-stage kidney disease requiring renal replacement therapy before ICU admission were included. Our objectives were to assess the incidence and risk factors for AKI and to describe its clinical and biological characteristics, particularly its urinary protein profile. Results: Seventy patients were included; 87% needed mechanical ventilation and 61% needed vasopressor during their ICU stay; 64.3% of patients developed AKI and half of them needed dialysis. Total and tubular proteinuria on day 1 were higher in patients with AKI, whereas glomerular proteinuria was similar in both groups. The main risk factor for AKI was shock at admission (OR = 5.47 (1.74−17.2), p < 0.01). Mortality on day 28 was higher in AKI (23/45, 51.1%) than in no-AKI patients (1/25, 4%), p < 0.001. Risk factors for 28-days mortality were AKI with need for renal replacement therapy, non-renal SOFA score and history of congestive heart failure. Conclusions: AKI is common in COVID-19 patients hospitalized in ICU; it seems to be related to tubular lesions rather than glomerular injury and is related to shock at ICU admission.
Collapse
Affiliation(s)
- Romain Arrestier
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
- Correspondence: ; Tel.: +33-01-4981-2399; Fax: +33-01-4981-2542
| | - Ségolène Gendreau
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
| | - David Mokrani
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
| | - Jean-Philippe Bastard
- Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (J.-P.B.); (S.F.)
- Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris Est Créteil, 94010 Creteil, France;
| | - Soraya Fellahi
- Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (J.-P.B.); (S.F.)
- Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Institut National de la Santé et de la Recherche Médicale (INSERM) UMR S938, Sorbonne Université, 75006 Paris, France
| | - François Bagate
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
| | - Paul Masi
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
| | - Thomas d’Humières
- Service de Physiologie Explorations Fonctionnelles, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France
| | - Keyvan Razazi
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
| | - Guillaume Carteaux
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris Est Créteil, 94010 Creteil, France;
| | - Nicolas De Prost
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
| | - Vincent Audard
- Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris Est Créteil, 94010 Creteil, France;
- Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France
| | - Armand Mekontso-Dessap
- Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Creteil, France; (S.G.); (D.M.); (F.B.); (P.M.); (K.R.); (G.C.); (N.D.P.); (A.M.-D.)
- GRC CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Creteil, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris Est Créteil, 94010 Creteil, France;
| |
Collapse
|
9
|
Antuna-Puente B, Fellahi S, McAvoy C, Fève B, Bastard JP. Interleukins in adipose tissue: Keeping the balance. Mol Cell Endocrinol 2022; 542:111531. [PMID: 34910978 DOI: 10.1016/j.mce.2021.111531] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 12/01/2021] [Accepted: 12/08/2021] [Indexed: 02/06/2023]
Abstract
The role of the immune system is to defend the host and preserve the functionality in response to stress. This function is not limited to infection or injury as it also plays a role in the response to overnutrition. Indeed, low-grade chronic activation of the immune system associated with overnutrition may be deleterious, contributing importantly to diabetes and long-term complications, such as cardiovascular disorders. Increasing evidence shows that adipose tissue participates in the obesity-related inflammatory response and that interleukins are one of the key players, either as a pro-inflammatory response to the metabolic dysregulation or to restore homeostasis. The crosstalk between adipocytes and immune cells through some important interleukins and their role in metabolic disruption is the topic of this review.
Collapse
Affiliation(s)
- Barbara Antuna-Puente
- Infection Disease Division, Department of Medicine, Queen's University, Kingston, ON, Canada.
| | - Soraya Fellahi
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-pharmacologie-biologie Moléculaire-génétique Médicale, Créteil, France; Sorbonne Université-Inserm, Centre de Recherche Saint-Antoine UMR S_938, 75012, Paris Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris, France
| | - Chloé McAvoy
- Unité de Recherche Clinique de L'Est Parisien (URC-Est), Hôpital Saint Antoine, Paris, France
| | - Bruno Fève
- Sorbonne Université-Inserm, Centre de Recherche Saint-Antoine UMR S_938, 75012, Paris Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris, France; Assistance Publique- Hôpitaux de Paris -Hôpital Saint-Antoine, Service D'Endocrinologie-Diabétologie, Centre de Référence des Maladies Rares de L'Insulino-Sécrétion et de L'Insulino-Sensibilité (PRISIS), 75012, Paris, France
| | - Jean-Philippe Bastard
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-pharmacologie-biologie Moléculaire-génétique Médicale, Créteil, France; FHU-SENEC, INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de Santé, Créteil, France
| |
Collapse
|
10
|
Mariette X, Hermine O, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Yazdanpanah Y, Baron G, Perrodeau E, Vanhoye D, Kedzia C, Demerville L, Gysembergh-Houal A, Bourgoin A, Dalibey S, Raked N, Mameri L, Alary S, Hamiria S, Bariz T, Semri H, Hai DM, Benafla M, Belloul M, Vauboin P, Flamand S, Pacheco C, Walter-Petrich A, Stan E, Benarab S, Nyanou C, Montlahuc C, Biard L, Charreteur R, Dupré C, Cardet K, Lehmann B, Baghli K, Madelaine C, D'Ortenzio E, Puéchal O, Semaille C, Savale L, Harrois A, Figueiredo S, Duranteau J, Anguel N, Pavot A, Monnet X, Richard C, Teboul JL, Durand P, Tissieres P, Jevnikar M, Montani D, Bulifon S, Jaïs X, Sitbon O, Pavy S, Noel N, Lambotte O, Escaut L, Jauréguiberry S, Baudry E, Verny C, Noaillon M, Lefèvre E, Zaidan M, Le Tiec CLT, Verstuyft C, Roques AM, Grimaldi L, Molinari D, Leprun G, Fourreau A, Cylly L, Virlouvet M, Meftali R, Fabre S, Licois M, Mamoune A, Boudali Y, Georgin-Lavialle S, Senet P, Pialoux G, Soria A, Parrot A, François H, Rozensztajn N, Blin E, Choinier P, Camuset J, Rech JS, Canellas A, Rolland-Debord C, Lemarié N, Belaube N, Nadal M, Siguier M, Petit-Hoang C, Chas J, Drouet E, Lemoine M, Phibel A, Aunay L, Bertrand E, Ravato S, Vayssettes M, Adda A, Wilpotte C, Thibaut P, Fillon J, Debrix I, Fellahi S, Bastard JP, Lefèvre G, Fallet V, Gottenberg JE, Hansmann Y, Andres E, Bayer S, Becker G, Blanc F, Brin S, Castelain V, Chatelus E, Chatron E, Collange O, Danion F, De Blay F, Demonsant E, Diemunsch P, Diemunsch S, Felten R, Goichot B, Greigert V, Guffroy A, Heger B, Hutt A, Kaeuffer C, Kassegne L, Korganow AS, Le Borgne P, Lefebvre N, Martin T, Mertes PM, Metzger C, Meyer N, Nisand G, Noll E, Oberlin M, Ohlmann-Caillard S, Poindron V, Pottecher J, Ruch Y, Sublon C, Tayebi H, Weill F, Mekinian A, Abisror N, Jachiet V, Chopin D, Fain O, Garnier M, Krause le Garrec J, Morgand M, Pacanowski J, Urbina T, McAvoy C, Pereira M, Aratus G, Berard L, Simon T, Daguenel-Nguyen A, Antignac M, Leplay C, Arlet JB, Diehl JL, Bellenfant F, Blanchard A, Buffet A, Cholley B, Fayol A, Flamarion E, Godier A, Gorget T, Hamada SR, Hauw-Berlemont C, Hulot JS, Lebeaux D, Livrozet M, Michon A, Neuschwander A, Penet MA, Planquette B, Ranque B, Sanchez O, Volle G, Briois S, Cornic M, Elisee V, Jesuthasan D, Djadi-Prat J, Jouany P, Junquera R, Henriques M, Kebir A, Lehir I, Meunier J, Patin F, Paquet V, Tréhan A, Vigna V, Sabatier B, Bergerot D, Jouve C, Knosp C, Lenoir O, Mahtal N, Resmini L, Lescure FX, Ghosn J, BACHELARD A, BIRONNE T, BORIE R, BOUNHIOL A, BOUSSARD C, CHAUFFiER J, CHALAL S, CHALAL L, CHANSOMBAT M, CRESPIN P, CRESTANI B, DACONCEICAO O, DECONINCK L, DIEUDE P, DOSSIER A, DUBERT M, DUCROCQ G, FUENTES A, GERVAIS A, GILBERT M, ISERNIA V, ISMAEL S, JOLY V, JULIA Z, LARIVEN S, LE GAC S, LE PLUART D, LOUNI F, NDIAYE A, PAPO T, PARISEY M, PHUNG B, POURBAIX A, RACHLINE A, RIOUX C, SAUTEREAU A, STEG G, TARHINI H, VALAYER S, VALLOIS D, VERMES P, VOLPE T, Nguyen Y, Honsel V, Weiss E, Codorniu A, Zarrouk V, De Lastours V, Uzzan M, Olivier O, Rossi G, Gamany N, Rahli R, Louis Z, Boutboul D, Galicier L, Amara Y, Archer G, Benattia A, Bergeron A, Bondeelle L, De Castro N, Clément M, Darmont M, Denis B, Dupin C, Feredj E, Feyeux D, Joseph A, Lengliné E, Le Guen P, Liégeon G, Lorillon G, Mabrouki A, Mariotte E, Martin de Frémont G, Mirouse A, Molina JM, Peffault de Latour R, Oksenhendler E, Saussereau J, Tazi A, Tudesq JJ, Zafrani L, Brindele I, Bugnet E, Celli Lebras K, Chabert J, Djaghout L, Fauvaux C, Jegu AL, Kozaliewicz E, Meunier M, Tremorin MT, Davoine C, Madeleine I, Caillat-Zucman S, Delaugerre C, Morin F, SENE D, BURLACU R, CHOUSTERMAN B, MEGARBANE B, RICHETTE P, RIVELINE JP, FRAZIER A, VICAUT E, BERTON L, HADJAM T, VASQUEZ-IBARRA MA, JOURDAINE C, JACOB A, SMATI J, RENAUD S, MANIVET P, PERNIN C, SUAREZ L, Semerano L, ABAD S, Benainous R, Bloch Queyrat C, Bonnet N, Brahmi S, Cailhol J, Cohen Y, Comparon C, Cordel H, Dhote R, Dournon N, Duchemann B, Ebstein N, Giroux-Leprieur B, Goupil de Bouille J, Jacolot A, Nunes H, Oziel J, Rathouin V, Rigal M, Roulot D, Tantet C, Uzunhan Y, COSTEDOAT-CHALUMEAU N, Ait Hamou Z, Benghanem S, BLANCHE P, CANOUI E, CARLIER N, CHAIGNE B, CONTEJEAN A, DUNOGUE B, DUPLAND P, DUREL - MAURISSE A, GAUZIT R, JAUBERT P, Joumaa H, Jozwiak M, KERNEIS S, LACHATRE M, Lafoeste H, LEGENDRE P, LUONG NGUYEN LB, MAREY J, MORBIEU C, MOUTHON L, NGUYEN L, Palmieri LJ, REGENT A, SZWEBEL TA, TERRIER B, GUERIN C, ZERBIT J, CHEREF K, CHITOUR K, CISSE MS, CLARKE A, CLAVERE G, DUSANTER I, GAUDEFROY C, JALLOULI M, KOLTA S, LE BOURLOUT C, MARIN N, MENAGE N, MOORES A, PEIGNEY I, PIERRON C, SALEH-MGHIR S, VALLET M, MICHEL M, MELICA G, LELIEVRE JD, FOIS E, LIM P, MATIGNON M, GUILLAUD C, THIEMELE A, SCHMITZ D, BOUHRIS M, BELAZOUZ S, LANGUILLE L, MEKONTSO-DESSAPS A, SADAOUI T, Mayaux J, Cacoub P, Corvol JC, Louapre C, Sambin S, Mariani LL, Karachi C, Tubach F, Estellat C, Gimeno L, Martin K, Bah A, Keo V, Ouamri S, Messaoudi Y, Yelles N, Faye P, Cavelot S, Larcheveque C, Annonay L, Benhida J, Zahrate-Ghoul A, Hammal S, Belilita R, Lecronier M, Beurton A, Haudebourg L, Deleris R, Le Marec J, Virolle S, Nemlaghi S, Bureau C, Mora P, De Sarcus M, Clovet O, Duceau B, Grisot PH, Pari MH, Arzoine J, Clarac U, Faure M, Delemazure J, Decavele M, Morawiec E, Demoule A, Dres M, Vautier M, Allenbach Y, Benveniste O, Leroux G, Rigolet A, Guillaume-Jugnot P, Domont F, Desbois AC, Comarmond C, Champtiaux N, Toquet S, Ghembaza A, Vieira M, Maalouf G, Boleto G, Ferfar Y, Charbonnier F, AGUILAR C, ALBY-LAURENT F, ALYANAKIAN MA, BAKOUBOULA P, BROISSAND C, BURGER C, CAMPOS-VEGA C, CHAVAROT N, CHOUPEAUX L, FOURNIER B, GRANVILLE S, ISSORAT E, ROUZAUD C, VIMPERE D, Geri G, Derridj N, Sguiouar N, Meddah H, Djadel M, Chambrin-Lauvray H, Duclos-Vallée JC, Saliba F, Sacleux SC, Koumis I, Michot JM, Stoclin A, Colomba E, Pommeret F, Willekens C, Sakkal M, Da Silva R, Dejean V, Mekid Y, Ben-Mabrouk I, Pradon C, Drouard L, Camara-Clayette V, Morel A, Garcia G, Mohebbi A, Berbour F, Dehais M, Pouliquen AL, Klasen A, Soyez-Herkert L, London J, Keroumi Y, Guillot E, Grailles G, El Amine Y, Defrancq F, Fodil H, Bouras C, Dautel D, Gambier N, Dieye T, Razurel A, Bienvenu B, Lancon V, Lecomte L, Beziriganyan K, Asselate B, Allanic L, Kiouris E, Legros MH, Lemagner C, Martel P, Provitolo V, Ackermann F, Le Marchand M, Clan Hew Wai A, Fremont D, Coupez E, Adda M, Duée F, Bernard L, Gros A, Henry E, Courtin C, Pattyn A, Guinot PG, Bardou M, Maurer A, Jambon J, Cransac A, Pernot C, Mourvillier B, Servettaz A, Deslée G, Wynckel A, Benoit P, Marquis E, Roux D, Gernez C, Yelnik C, Poissy J, Nizard M, Denies F, Gros H, Mourad JJ, Sacco E, Renet S. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology 2022; 4:e24-e32. [PMID: 34812424 PMCID: PMC8598187 DOI: 10.1016/s2665-9913(21)00315-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Background Patients with COVID-19 pneumonia can have increased inflammation and elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a high-affinity anti-IL-6 receptor antibody, might improve the outcome of patients with moderate-to-severe COVID-19 pneumonia. Methods We did a multicentric, open-label, Bayesian randomised, adaptive, phase 2/3 clinical trial, nested within the CORIMUNO-19 cohort, to test a superiority hypothesis. Patients 18 years or older hospitalised with COVID-19 in six French centres, requiring at least 3L/min of oxygen but without ventilation assistance and a WHO Clinical Progression Scale [CPS] score of 5 were enrolled. Patients were randomly assigned (1:1) via a web-based system, according to a randomisation list stratified on centre and with blocks randomly selected among 2 and 4, to receive usual care plus 400 mg of sarilumab intravenously on day 1 and on day 3 if clinically indicated (sarilumab group) or usual care alone (usual care group). Primary outcomes were the proportion of patients with WHO-CPS scores greater than 5 on the 10-point scale on day 4 and survival without invasive or non-invasive ventilation at day 14. This completed trial is closed to new participants and is registered with ClinicalTrials.gov, NCT04324073. Findings 165 patients were recruited from March 27 to April 6, 2020, and 148 patients were randomised (68 patients to the sarilumab group and 80 to the usual care group) and followed up for 90 days. Median age was 61·7 years [IQR 53·0–71·1] in the sarilumab group and 62·8 years [56·0–71·7] in the usual care group. In the sarilumab group 49 (72%) of 68 were men and in the usual care group 59 (78%) of 76 were men. Four patients in the usual care group withdrew consent and were not analysed. 18 (26%) of 68 patients in the sarilumab group had a WHO-CPS score greater than 5 at day 4 versus 20 (26%) of 76 in the usual care group (median posterior absolute risk difference 0·2%; 90% credible interval [CrI] −11·7 to 12·2), with a posterior probability of absolute risk difference greater than 0 of 48·9%. At day 14, 25 (37%) patients in the sarilumab and 26 (34%) patients in the usual care group needed ventilation or died, (median posterior hazard ratio [HR] 1·10; 90% CrI 0·69–1·74) with a posterior probability HR greater than 1 of 37·4%. Serious adverse events occurred in 27 (40%) patients in the sarilumab group and 28 (37%) patients in the usual care group (p=0·73). Interpretation Sarilumab treatment did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia. Further studies are warranted to evaluate the effect of sarilumab on long-term survival. Funding Assistance publique—Hôpitaux de Paris
Collapse
|
11
|
Fumeron F, El Boustany R, Bastard JP, Fellahi S, Balkau B, Marre M, Venteclef N, Velho G, Roussel R. Plasma total adiponectin and changes in renal function in a cohort from the community: the prospective Data from an Epidemiological Study on the Insulin Resistance Syndrome study. Nephrol Dial Transplant 2021; 36:2058-2065. [PMID: 33141880 DOI: 10.1093/ndt/gfaa228] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND High adiponectin levels are associated with diabetic nephropathy. Nevertheless, it is not known whether plasma adiponectin is associated with renal function decline in the general population. We evaluated whether adiponectin concentrations were associated with changes in renal function in a community cohort, the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. METHODS Plasma adiponectin concentrations were measured in a random sample of 3284 people from the DESIR study, a 9-year prospective cohort from the general population. Data were analysed for three endpoints during follow-up: incidence of Stage 3 chronic kidney disease (CKD); the Kidney Disease: Improving Global Outcomes (KDIGO) criterion 'certain drop in eGFR' and rapid kidney function decline [estimated glomerular filtration rate (eGFR) slope steeper than -3 mL/min/1.73 m2/year]. RESULTS After exclusion of participants with an eGFR <60 mL/min/1.73 m2 at baseline and those with type 2 diabetes or impaired fasting glycaemia at any time during follow-up (remaining n = 2174), there was a 113% higher risk for a rapid decline in kidney function in participants with adiponectin above the third tertile (T3) versus below the first tertile (T1) (Ptrend = 0.004) and a 53% higher risk for kidney function decline as defined by the KDIGO criterion (Ptrend = 0.04). In a cross-sectional analysis, adiponectin was positively associated with urinary albumin:creatinine ratio at baseline (P = 0.009). CONCLUSIONS In a healthy cohort from the general population, higher levels of plasma adiponectin were associated with decreased renal function at baseline and at follow-up. This result is similar to what is observed in people with diabetic nephropathy, in contrast with animal models of nephropathy.
Collapse
Affiliation(s)
| | - Ray El Boustany
- Centre de Recherche des Cordeliers UMR-S 1138, Université de Paris, INSERM, Paris, France
| | - Jean-Philippe Bastard
- Biochemistry and Hormonology Department, AP-HP, Tenon Hospital, Paris, France.,Department of Biochemistry-Pharmacology-Molecular Biology-Medical Genetics, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Soraya Fellahi
- Biochemistry and Hormonology Department, AP-HP, Tenon Hospital, Paris, France
| | - Beverley Balkau
- Centre for Research in Epidemiology and Population Health (CESP), INSERM, UMR-S 1018, University Paris-Sud, University Versailles Saint-Quentin, Villejuif, France
| | - Michel Marre
- Centre de Recherche des Cordeliers UMR-S 1138, Université de Paris, INSERM, Paris, France
| | - Nicolas Venteclef
- Centre de Recherche des Cordeliers UMR-S 1138, Université de Paris, INSERM, Paris, France.,UMR-S 1138, Sorbonne Université, Paris, France
| | | | - Ronan Roussel
- Centre de Recherche des Cordeliers UMR-S 1138, Université de Paris, INSERM, Paris, France.,Department of Diabetology, Endocrinology, Nutrition, AP-HP, Bichat Hospital, Paris, France
| |
Collapse
|
12
|
Bastard JP, Pelloux V, Alili R, Fellahi S, Aron-Wisnewsky J, Capel E, Fève B, Assoumou L, Prifti E, Katlama C, Clément K, Capeau J. Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc. AIDS 2021; 35:1625-1630. [PMID: 33831906 DOI: 10.1097/qad.0000000000002900] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To evaluate the effect on anthropometric, metabolic and adipose tissue parameters of switching ART-controlled persons living with HIV (PLWH) from a protease inhibitor regimen to raltegravir/maraviroc. DESIGN Sub-study of the ANRS157 ROCnRAL study with the investigation of subcutaneous abdominal adipose tissue (SCAT) biopsy at inclusion and study end. METHODS We performed lipoaspiration of paired SCAT samples, histology on fresh/fixed samples and examined the transcriptomic profile analyzed using Illumina microarrays after RNA extraction. Statistical analyses used the Wilcoxon-paired test. RESULTS The patients (n = 8) were mainly male (7/8), aged (mean ± standard error of the mean) 54.9 ± 1.2 years, BMI 26.1 ± 1.2 kg/m2, CD4+ 699 ± 56 cells/mm3, all viral load (VL) <50 copies/ml. After a follow-up of 6 ± 0.5 months, all PLWH remained with VL <50 copies/ml. BMI, trunk and limb fat amounts were unchanged yet systemic insulin resistance increased. Adipose tissue histology was unchanged except for borderline increased adipocyte diameter (P = 0.1). Among the 16 094 RNA transcripts, 458 genes were up-regulated and 244 were down-regulated. Analyses of the Kyoto Encyclopedia of Genes and Genomes and Gene Ontology databases, evaluating modifications in the main functional pathways, revealed that genes related to immune recognition/function were less expressed as were genes encoding T-cell receptor and receptor signaling pathways. The gene expression profiles indicated decreased inflammation but genes involved in adipogenesis and insulin resistance were overexpressed. CONCLUSION After 6 months of raltegravir/maraviroc, adipogenesis-related gene profile was enhanced in SCAT, in agreement with a tendency for increased adipocyte size. Enhanced SCAT insulin resistance-related profile was concordant with higher systemic insulin resistance. However, the immune activation/inflammation profile was globally lowered. We propose that raltegravir/maraviroc might favor SCAT gain but reduce inflammation/immune activation.
Collapse
Affiliation(s)
- Jean-Philippe Bastard
- Sorbonne Université, Inserm, Faculty of Medicine, Centre de Recherche Saint-Antoine (CRSA), ICAN, Paris
- Department of Biochemistry-Pharmacology-Molecular Biology, APHP, Henri-Mondor Hospital, Université Paris Est Créteil
| | - Véronique Pelloux
- Sorbonne Université, Inserm, Faculty of Medicine, Nutrition and Obesities: Systemic Approaches (NutriOmics)
- Assistance Publique Hôpitaux de Paris, Sorbonne Université, Nutrition Department, Pitié-Salpétrière hospital, CRNH Ile-de-France, GH APHP-Sorbonne Université
| | - Rohia Alili
- Sorbonne Université, Inserm, Faculty of Medicine, Nutrition and Obesities: Systemic Approaches (NutriOmics)
- Assistance Publique Hôpitaux de Paris, Sorbonne Université, Nutrition Department, Pitié-Salpétrière hospital, CRNH Ile-de-France, GH APHP-Sorbonne Université
| | - Soraya Fellahi
- Sorbonne Université, Inserm, Faculty of Medicine, Centre de Recherche Saint-Antoine (CRSA), ICAN, Paris
| | - Judith Aron-Wisnewsky
- Sorbonne Université, Inserm, Faculty of Medicine, Nutrition and Obesities: Systemic Approaches (NutriOmics)
- Assistance Publique Hôpitaux de Paris, Sorbonne Université, Nutrition Department, Pitié-Salpétrière hospital, CRNH Ile-de-France, GH APHP-Sorbonne Université
| | - Emilie Capel
- Sorbonne Université, Inserm, Faculty of Medicine, Centre de Recherche Saint-Antoine (CRSA), ICAN, Paris
| | - Bruno Fève
- Sorbonne Université, Inserm, Faculty of Medicine, Centre de Recherche Saint-Antoine (CRSA), ICAN, Paris
- Department of Endocrinology, CRMR Prisis, Saint-Antoine Hospital, GH APHP-Sorbonne Université
| | - Lambert Assoumou
- Sorbonne Université, Inserm, Faculty of Medicine, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris
| | - Edi Prifti
- IRD, Sorbonne University, UMMISCO, Bondy
| | - Christine Katlama
- Sorbonne Université, Inserm, Faculty of Medicine, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris
- Department of Infectious Diseases, Pitié-Salpétrière Hospital, GH APHP-Sorbonne Université, Paris, France
| | - Karine Clément
- Sorbonne Université, Inserm, Faculty of Medicine, Nutrition and Obesities: Systemic Approaches (NutriOmics)
- Assistance Publique Hôpitaux de Paris, Sorbonne Université, Nutrition Department, Pitié-Salpétrière hospital, CRNH Ile-de-France, GH APHP-Sorbonne Université
| | - Jacqueline Capeau
- Sorbonne Université, Inserm, Faculty of Medicine, Centre de Recherche Saint-Antoine (CRSA), ICAN, Paris
| |
Collapse
|
13
|
Ghosn J, Abdoul H, Fellahi S, Merlet A, Salmon D, Morini JP, Deleuze J, Blacher J, Capeau J, Bastard JP, Viard JP. Prevalence of Silent Atherosclerosis and Other Comorbidities in an Outpatient Cohort of Adults Living with HIV: Associations with HIV Parameters and Biomarkers. AIDS Res Hum Retroviruses 2021; 37:101-108. [PMID: 33076677 DOI: 10.1089/aid.2020.0182] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
People living with HIV (PLWH) are at risk of noninfectious comorbidities. It is important to individualize those at higher risk. In a single-center cohort of PLWH, we performed a cross-sectional analysis of comorbidities, diagnosed according to standard procedures. The primary endpoint was the prevalence of subclinical carotid/coronary atherosclerosis. Secondary endpoints were its association with selected inflammatory/immune activation biomarkers and with other comorbidities. Associations were examined by using Chi-square or Fisher's exact test for categorical variables and Student or Wilcoxon tests for quantitative variables, and a stepwise multivariate logistical model was performed for further exploration. Among 790 participants [median age: 49.8 years (interquartile range, IQR: 44.5-55.6), 77.1% males, median CD4: 536/mm3 (IQR: 390-754), 83.6% with undetectable viral load], asymptomatic atherosclerosis was found in 26% and was associated in multivariate analysis with older age, longer known duration of infection, higher sCD14, and lower adiponectin levels. Hypertension was found in 33.5% of participants, diabetes in 19.4%, renal impairment in 14.6%, elevated low-density lipoprotein-cholesterol in 13.3%, elevated triglyceride/high-density lipoprotein (HDL)-cholesterol ratio in 6.6%, and osteoporosis in 7.9%. The presence of two or more comorbidities was found in 42.1% of participants and was associated in multivariate analysis with older age and longer exposure to antiretrovirals. Comorbidities were diversely associated with biomarkers: osteoporosis with higher IL-6, renal impairment with higher sCD14, hypertension with higher D-dimer, diabetes and elevated triglyceride/HDL-cholesterol ratio both with lower adiponectin and lower 25-hydroxyvitamin D. Asymptomatic atherosclerosis and multimorbidity were frequent in a cohort of middle-aged, well-controlled, PLWH and were associated with traditional and HIV-specific factors. Associations between morbidities and inflammatory/immune activation biomarkers were diverse.
Collapse
Affiliation(s)
- Jade Ghosn
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Hendy Abdoul
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Soraya Fellahi
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Audrey Merlet
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Dominique Salmon
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Jean-Pierre Morini
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Jean Deleuze
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Jacques Blacher
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Jacqueline Capeau
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Jean-Philippe Bastard
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| | - Jean-Paul Viard
- Immunology-Infectious Diseases Unit, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Centre-Université de Paris, Paris, France
| |
Collapse
|
14
|
Molinaro A, Bel Lassen P, Henricsson M, Wu H, Adriouch S, Belda E, Chakaroun R, Nielsen T, Bergh PO, Rouault C, André S, Marquet F, Andreelli F, Salem JE, Assmann K, Bastard JP, Forslund S, Le Chatelier E, Falony G, Pons N, Prifti E, Quinquis B, Roume H, Vieira-Silva S, Hansen TH, Pedersen HK, Lewinter C, Sønderskov NB, Køber L, Vestergaard H, Hansen T, Zucker JD, Galan P, Dumas ME, Raes J, Oppert JM, Letunic I, Nielsen J, Bork P, Ehrlich SD, Stumvoll M, Pedersen O, Aron-Wisnewsky J, Clément K, Bäckhed F. Author Correction: Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun 2020; 11:6448. [PMID: 33349634 PMCID: PMC7752903 DOI: 10.1038/s41467-020-20412-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Antonio Molinaro
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden.,Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Pierre Bel Lassen
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France.,Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France
| | - Marcus Henricsson
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Hao Wu
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Solia Adriouch
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Eugeni Belda
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France.,Integromics Unit, Institute of Cardiometabolism and Nutrition, 75013, Paris, France
| | - Rima Chakaroun
- Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Trine Nielsen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Per-Olof Bergh
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Christine Rouault
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Sébastien André
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Florian Marquet
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Fabrizio Andreelli
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Joe-Elie Salem
- Assistance Publique Hôpitaux de Paris, Clinical Investigation Center Paris East, 75013, Paris, France
| | - Karen Assmann
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Jean-Philippe Bastard
- Assistance Publique Hôpitaux de Paris, Biochemistry and Hormonology Department, Tenon Hospital, 75020, Paris, France
| | - Sofia Forslund
- Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin and the Max-Delbrück Center, Berlin, Germany
| | | | - Gwen Falony
- Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium.,Center for Microbiology, VIB, Leuven, Belgium
| | - Nicolas Pons
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Edi Prifti
- Integromics Unit, Institute of Cardiometabolism and Nutrition, 75013, Paris, France.,Unité de Modélisation Mathématique et Informatique des Systèmes Complexes, UMMISCO, 93143, Bondy, France
| | - Benoit Quinquis
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Hugo Roume
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Sara Vieira-Silva
- Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium.,Center for Microbiology, VIB, Leuven, Belgium
| | - Tue H Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Helle Krogh Pedersen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Christian Lewinter
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Nadja B Sønderskov
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | | | - Lars Køber
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Henrik Vestergaard
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Torben Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Jean-Daniel Zucker
- Unité de Modélisation Mathématique et Informatique des Systèmes Complexes, UMMISCO, 93143, Bondy, France
| | - Pilar Galan
- Sorbonne Paris Cité Epidemiology and Statistics Research Centre (CRESS), U1153 Inserm, U1125, Inra, Cnam, University of Paris 13, Nutritional Epidemiology Research Team (EREN), 93017, Bobigny, France
| | - Marc-Emmanuel Dumas
- Computational and Systems Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, SW7 2AZ, UK.,Genomic and Environmental Medicine, National Heart & Lung Institute, Faculty of Medicine, Imperial College London, London, SW3 6KY, UK
| | - Jeroen Raes
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France.,Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium
| | - Jean-Michel Oppert
- Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France
| | - Ivica Letunic
- Biobyte Solutions GmbH, Bothestr. 142, 69117, Heidelberg, Germany
| | - Jens Nielsen
- Department of Biology and Biological Engineering, Chalmers University of Technology, SE41128, Gothenburg, Sweden
| | - Peer Bork
- Structural and Computational Biology, European Molecular Biology Laboratory, Heidelberg, Germany.,Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany
| | - S Dusko Ehrlich
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Michael Stumvoll
- Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Oluf Pedersen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Judith Aron-Wisnewsky
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France.,Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France
| | - Karine Clément
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France. .,Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France.
| | - Fredrik Bäckhed
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden. .,Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. .,Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
| |
Collapse
|
15
|
Molinaro A, Bel Lassen P, Henricsson M, Wu H, Adriouch S, Belda E, Chakaroun R, Nielsen T, Bergh PO, Rouault C, André S, Marquet F, Andreelli F, Salem JE, Assmann K, Bastard JP, Forslund S, Le Chatelier E, Falony G, Pons N, Prifti E, Quinquis B, Roume H, Vieira-Silva S, Hansen TH, Pedersen HK, Lewinter C, Sønderskov NB, Køber L, Vestergaard H, Hansen T, Zucker JD, Galan P, Dumas ME, Raes J, Oppert JM, Letunic I, Nielsen J, Bork P, Ehrlich SD, Stumvoll M, Pedersen O, Aron-Wisnewsky J, Clément K, Bäckhed F. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun 2020; 11:5881. [PMID: 33208748 PMCID: PMC7676231 DOI: 10.1038/s41467-020-19589-w] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Accepted: 10/22/2020] [Indexed: 12/13/2022] Open
Abstract
Microbiota-host-diet interactions contribute to the development of metabolic diseases. Imidazole propionate is a novel microbially produced metabolite from histidine, which impairs glucose metabolism. Here, we show that subjects with prediabetes and diabetes in the MetaCardis cohort from three European countries have elevated serum imidazole propionate levels. Furthermore, imidazole propionate levels were increased in subjects with low bacterial gene richness and Bacteroides 2 enterotype, which have previously been associated with obesity. The Bacteroides 2 enterotype was also associated with increased abundance of the genes involved in imidazole propionate biosynthesis from dietary histidine. Since patients and controls did not differ in their histidine dietary intake, the elevated levels of imidazole propionate in type 2 diabetes likely reflects altered microbial metabolism of histidine, rather than histidine intake per se. Thus the microbiota may contribute to type 2 diabetes by generating imidazole propionate that can modulate host inflammation and metabolism. Gut microbial metabolism of nutrients contributes to metabolic diseases, and the histidine metabolite imidazole propionate (ImP) is produced by type 2 diabetes (T2D) associated microbiome. Here the authors report that circulating ImP levels are increased in subjects with prediabetes or T2D in three European populations, and this increase associates with altered gut microbiota rather than dietary histidine.
Collapse
Affiliation(s)
- Antonio Molinaro
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden.,Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Pierre Bel Lassen
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France.,Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France
| | - Marcus Henricsson
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Hao Wu
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Solia Adriouch
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Eugeni Belda
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France.,Integromics Unit, Institute of Cardiometabolism and Nutrition, 75013, Paris, France
| | - Rima Chakaroun
- Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Trine Nielsen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Per-Olof Bergh
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Christine Rouault
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Sébastien André
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Florian Marquet
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Fabrizio Andreelli
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Joe-Elie Salem
- Assistance Publique Hôpitaux de Paris, Clinical Investigation Center Paris East, 75013, Paris, France
| | - Karen Assmann
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France
| | - Jean-Philippe Bastard
- Assistance Publique Hôpitaux de Paris, Biochemistry and Hormonology Department, Tenon Hospital, 75020, Paris, France
| | - Sofia Forslund
- Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin and the Max-Delbrück Center, Berlin, Germany
| | | | - Gwen Falony
- Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium.,Center for Microbiology, VIB, Leuven, Belgium
| | - Nicolas Pons
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Edi Prifti
- Integromics Unit, Institute of Cardiometabolism and Nutrition, 75013, Paris, France.,Unité de Modélisation Mathématique et Informatique des Systèmes Complexes, UMMISCO, 93143, Bondy, France
| | - Benoit Quinquis
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Hugo Roume
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Sara Vieira-Silva
- Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium.,Center for Microbiology, VIB, Leuven, Belgium
| | - Tue H Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Helle Krogh Pedersen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Christian Lewinter
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Nadja B Sønderskov
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | | | - Lars Køber
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Henrik Vestergaard
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Torben Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Jean-Daniel Zucker
- Unité de Modélisation Mathématique et Informatique des Systèmes Complexes, UMMISCO, 93143, Bondy, France
| | - Pilar Galan
- Sorbonne Paris Cité Epidemiology and Statistics Research Centre (CRESS), U1153 Inserm, U1125, Inra, Cnam, University of Paris 13, Nutritional Epidemiology Research Team (EREN), 93017, Bobigny, France
| | - Marc-Emmanuel Dumas
- Computational and Systems Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, SW7 2AZ, UK.,Genomic and Environmental Medicine, National Heart & Lung Institute, Faculty of Medicine, Imperial College London, London, SW3 6KY, UK
| | - Jeroen Raes
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France.,Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium
| | - Jean-Michel Oppert
- Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France
| | - Ivica Letunic
- Biobyte Solutions GmbH, Bothestr. 142, 69117, Heidelberg, Germany
| | - Jens Nielsen
- Department of Biology and Biological Engineering, Chalmers University of Technology, SE41128, Gothenburg, Sweden
| | - Peer Bork
- Structural and Computational Biology, European Molecular Biology Laboratory, Heidelberg, Germany.,Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany
| | - S Dusko Ehrlich
- Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Paris, France
| | - Michael Stumvoll
- Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Oluf Pedersen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Judith Aron-Wisnewsky
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France.,Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France
| | - Karine Clément
- INSERM, Nutrition and Obesities; Systemic Approaches (NutriOmics), Sorbonne Université, Paris, France. .,Assistance Publique Hôpitaux de Paris, Pitie-Salpêtrière Hospital, Nutrition department, CRNH Ile de France, Paris, France.
| | - Fredrik Bäckhed
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, 413 45, Gothenburg, Sweden. .,Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. .,Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
| |
Collapse
|
16
|
Lescure FX, Fellahi S, Pialoux G, Bastard JP, Eme AL, Esteve E, Lebrette MG, Guiard-Schmid JB, Capeau J, Ronco P, Costagliola D, Plaisier E. Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. Nephrol Dial Transplant 2020; 35:607-615. [PMID: 31071216 DOI: 10.1093/ndt/gfz081] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 03/27/2019] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The incidence of chronic kidney disease (CKD) is 10 times higher in human immunodeficiency virus (HIV)-infected patients than in the general population. We explored the prevalence and determinants of proximal tubular dysfunction (PTD) in HIV-infected individuals, and assessed the impact of the tubulopathy on the estimated glomerular filtration rate (eGFR) outcome. METHODS A cohort study was performed on 694 outpatients followed in a French centre to analyse the prevalence of PTD, the diagnosis performance of screening tools and the associated factors. eGFR was prospectively evaluated to analyse the predictive value of the tubulopathy on eGFR decrease. RESULTS At inclusion, 14% of the patients presented with PTD and 5% with CKD. No individual tubular marker, including non-glomerular proteinuria, glycosuria dipstick or hypophosphataemia, registered sufficient performance to identify PTD. We found a significant interaction between tenofovir disoproxil fumarate exposure and ethnicity (P = 0.03) for tubulopathy risk. Tenofovir disoproxil fumarate exposure was associated with PTD in non-Africans [adjusted odds ratio (aOR) = 4.71, P < 10-3], but not in patients of sub-Saharan African origin (aOR = 1.17, P = 0.73). Among the 601 patients followed during a median of 4.3 years, 13% experienced an accelerated eGFR decline. Unlike microalbuminuria and glomerular proteinuria, tubulopathy was not associated with accelerated eGFR decline. CONCLUSION PTD is not rare in HIV-infected individuals but is less frequent in sub-Saharan African patients and is associated with tenofovir disoproxil fumarate exposure only in non-Africans. Its diagnosis requires multiple biochemical testing and it is not associated with an accelerated eGFR decline.
Collapse
Affiliation(s)
- François-Xavier Lescure
- Department of Infectious and Tropical Diseases, Bichat Hospital, AP-HP, Paris, France.,Department of Infectious and Tropical Diseases, Tenon Hospital, AP-HP, Paris, France.,Inserm, IAME, UMRS 1137, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, Paris, France
| | - Soraya Fellahi
- Department of Biochemistry and Hormonology, Tenon Hospital, AP-HP, Paris, France.,Inserm UMR, Centre de Recherche Saint-Antoine, UMRS 938, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne University, UPMC, Paris, France.,Sorbonne Universités, Paris, France
| | - Gilles Pialoux
- Department of Infectious and Tropical Diseases, Tenon Hospital, AP-HP, Paris, France.,Inserm, IAME, UMRS 1137, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, Paris, France.,Department of Biochemistry and Hormonology, Tenon Hospital, AP-HP, Paris, France.,Inserm UMR, Centre de Recherche Saint-Antoine, UMRS 938, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne University, UPMC, Paris, France.,Sorbonne Universités, Paris, France
| | - Jean-Philippe Bastard
- Department of Biochemistry and Hormonology, Tenon Hospital, AP-HP, Paris, France.,Inserm UMR, Centre de Recherche Saint-Antoine, UMRS 938, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne University, UPMC, Paris, France.,Sorbonne Universités, Paris, France
| | - Anne-Line Eme
- Department of Infectious and Tropical Diseases, Bichat Hospital, AP-HP, Paris, France
| | - Emmanuel Esteve
- Department of Nephrology and Dialysis, Tenon Hospital, AP-HP, Paris, France
| | - Marie-Gisèle Lebrette
- Department of Infectious and Tropical Diseases, Tenon Hospital, AP-HP, Paris, France
| | | | - Jacqueline Capeau
- Department of Biochemistry and Hormonology, Tenon Hospital, AP-HP, Paris, France.,Inserm UMR, Centre de Recherche Saint-Antoine, UMRS 938, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne University, UPMC, Paris, France.,Sorbonne Universités, Paris, France
| | - Pierre Ronco
- Sorbonne Universités, Paris, France.,Department of Nephrology and Dialysis, Tenon Hospital, AP-HP, Paris, France.,Inserm, UMRS 1155, Paris, France
| | - Dominique Costagliola
- Sorbonne Universités, Paris, France.,INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique, IPLESP, Paris, France
| | - Emmanuelle Plaisier
- Sorbonne Universités, Paris, France.,Department of Nephrology and Dialysis, Tenon Hospital, AP-HP, Paris, France.,Inserm, UMRS 1155, Paris, France
| |
Collapse
|
17
|
Gorlier C, Sellam J, Laurans L, Simon T, Giurgea I, Bastard JP, Fellahi S, Deshayes S, Grateau G, Oufella HA, Georgin-Lavialle S. Response to Letter to the Editor. Innate Immun 2020; 26:232-233. [PMID: 32223386 PMCID: PMC7144028 DOI: 10.1177/1753425920908681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Clémence Gorlier
- Rheumatology Department, Assistance Publique - Hôpitaux de Paris, Saint-Antoine Hospital, France
| | - Jérémie Sellam
- Rheumatology Department, Assistance Publique - Hôpitaux de Paris, Saint-Antoine Hospital, France
| | - Ludivine Laurans
- Inserm U970, Paris Cardiovascular Research Centre, Université René Descartes, France
| | - Tabassome Simon
- Plateforme de Recherche Clinique de l'Est Parisien (URCEST-CRCEST-CRB), Assistance Publique - Hôpitaux de Paris, Saint-Antoine Hospital, France
| | - Irina Giurgea
- Département de Génétique médicale, Assistance Publique - Hôpitaux de Paris, Hôpital Trousseau, France
| | - Jean-Philippe Bastard
- Département de Biochimie, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, France
| | - Soraya Fellahi
- Département de Biochimie, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, France
| | - Samuel Deshayes
- Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, France.,Service de médecine interne, UNICAEN, CHU de Caen Normandie, France
| | - Gilles Grateau
- Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, France
| | - Hafid Ait Oufella
- Inserm U970, Paris Cardiovascular Research Centre, Université René Descartes, France.,Service de Réanimation-Médecine intensive, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, France
| | - Sophie Georgin-Lavialle
- Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, France
| |
Collapse
|
18
|
Elfassy Y, Bongrani A, Levy P, Foissac F, Fellahi S, Faure C, McAvoy C, Capeau J, Dupont J, Fève B, Levy R, Bastard JP. Relationships between metabolic status, seminal adipokines, and reproductive functions in men from infertile couples. Eur J Endocrinol 2020; 182:67-77. [PMID: 31705791 DOI: 10.1530/eje-19-0615] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 11/07/2019] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Adipokines could be a link between metabolic syndrome (MS) and infertility. While the association between circulating adipokines and fertility has been extensively studied in females, this relationship in males was less investigated, although some adipokines are detectable in seminal plasma (SP). The aim of this study was to determine adipokine levels in blood and SP and to assess the relationships between adipokines, MS and semen parameters in men from infertile couples. DESIGN Male partners of infertile couples referred to four medical French centers were enrolled in years 2013-2016. METHODS Subjects (n = 160) aged 18-45 years were assessed for anthropometric, biochemical, sperm, and circulating hormonal parameters. Leptin, adiponectin, resistin, chemerin, visfatin, and IL-6 were measured in serum and SP. RESULTS Infertility duration was higher in men with than without MS. Adipokine concentrations were higher in blood than in SP, except for IL-6 and visfatin. The most striking result was the significant correlation observed between seminal IL-6 and spermatozoid concentration, progressive motility, and sperm vitality. Moreover, while men with MS exhibited an expected lower adiponectinemia, they displayed 2.1-fold higher adiponectin levels in SP than men without MS. Finally, logistic regression analysis showed that BMI, infertility duration, and adiponectin serum/SP ratio were independently associated with MS. CONCLUSIONS These results suggest an involvement of seminal adipokines to modulate fertility in men with MS and that seminal IL-6 could play a beneficial role on sperm functionality. Further mechanistic studies are necessary to investigate the precise roles of these adipokines in male reproduction.
Collapse
Affiliation(s)
- Yaelle Elfassy
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Biologie de la Reproduction, Sorbonne Université, Paris, France
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| | - Alice Bongrani
- INRA, UMR85, Physiologie de la Reproduction et des Comportements, Nouzilly, France
| | - Pierre Levy
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Unité de Santé Publique, Sorbonne Université-INSERM UMR S_1136, Paris, France
- Institut Pierre-Louis de Santé Publique (EPAR Team), Paris, France
| | - Frantz Foissac
- Clinical Research Unit Necker-Cochin, Assistance Publique-Hopitaux de Paris, Paris, France
| | - Soraya Fellahi
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Paris, France
| | - Céline Faure
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Biologie de la Reproduction, Sorbonne Université, Paris, France
| | - Chloé McAvoy
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| | - Jacqueline Capeau
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| | - Joëlle Dupont
- INRA, UMR85, Physiologie de la Reproduction et des Comportements, Nouzilly, France
| | - Bruno Fève
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
- Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Antoine, Service d'Endocrinologie, Paris, France
| | - Rachel Levy
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Biologie de la Reproduction, Sorbonne Université, Paris, France
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| | - Jean-Philippe Bastard
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Paris, France
| |
Collapse
|
19
|
Boyd A, Boccara F, Meynard JL, Ichou F, Bastard JP, Fellahi S, Samri A, Sauce D, Haddour N, Autran B, Cohen A, Girard PM, Capeau J. Serum Tryptophan-Derived Quinolinate and Indole-3-Acetate Are Associated With Carotid Intima-Media Thickness and its Evolution in HIV-Infected Treated Adults. Open Forum Infect Dis 2019; 6:ofz516. [PMID: 31890722 PMCID: PMC6929253 DOI: 10.1093/ofid/ofz516] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Accepted: 12/05/2019] [Indexed: 11/14/2022] Open
Abstract
Background HIV-infected individuals undergoing effective antiretroviral therapy (ART) present an increased risk of atherosclerotic cardiovascular disease. We identified serum metabolites associated with carotid intima-media thickness (c-IMT) and its evolution. Methods One hundred forty-three hydrophilic serum metabolites were measured by ultraperformance liquid chromatography coupled with high-resolution mass spectrometry in 49 HIV+ ART+, 48 HIV+ ART-naïve and 50 HIV-negative, age-matched, never-smoking male triads. Metabolites differentially altered between groups ("features") were defined as having a Benjamini-Hochberg-adjusted P value <.05 from a t test and >0.25 log2 absolute mean fold change in metabolite levels. c-IMT was measured across 12 sites at inclusion in all individuals and at the carotid artery (cca) after a median of 5.1 years in 32 HIV+ ART+ individuals. The difference in c-IMT (cross-sectional analysis) and slope of cca-IMT regression/progression per year (longitudinal analysis) for each log10 (area) increase in metabolite level were estimated with linear regression. Results Compared with HIV-, metabolite features of HIV+ ART+ were increased N6,N6,N6-trimethyl-L-lysine and decreased ferulate and 5-hydroxy-L-tryptophan, whereas features of HIV+ ART-naïve were increased malate, kynurenine, 2-oxoglutarate, and indole-3-acetate and decreased succinate and 5-hydroxy-L-tryptophan. In HIV+ ART+ individuals, quinolinate and/or indole-3-acetate were positively associated with c-IMT (P < .03), cca-IMT (P < .03), and cca-IMT progression (P < .008). These associations were not observed in HIV+ ART-naïve or HIV-negative individuals. In HIV+ ART+ individuals, the metabolites xanthosine and uridine, from nucleotide metabolism, and g-butyrobetaine, from lysine/dietary choline degradation, were also positively or negatively associated with c-IMT and/or cca-IMT (all P < .01), but not its evolution. Conclusions In these highly selected HIV-positive ART-controlled males, 2 novel metabolites derived from tryptophan catabolism, indole-3-acetate and quinolinate, were associated with c-IMT and its progression.
Collapse
Affiliation(s)
- Anders Boyd
- Inserm UMR_S1136, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France
| | - Franck Boccara
- Department of Cardiology, AP-HP, Hôpital Saint-Antoine, Paris, France.,Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN, Paris, France
| | - Jean-Luc Meynard
- Department of Infectious Diseases, APHP, Hôpital Saint-Antoine, Paris, France
| | - Farid Ichou
- Institute of Cardiometabolism and Nutrition, ICAN, ICANalytics, Paris, France
| | - Jean-Philippe Bastard
- Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN, Paris, France.,Department of Biochemistry, APHP, Hôpital Tenon, Paris, France
| | - Soraya Fellahi
- Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN, Paris, France.,Department of Biochemistry, APHP, Hôpital Tenon, Paris, France
| | - Assia Samri
- Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Delphine Sauce
- Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Nabila Haddour
- Department of Cardiology, AP-HP, Hôpital Saint-Antoine, Paris, France
| | - Brigitte Autran
- Sorbonne Université, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Ariel Cohen
- Department of Cardiology, AP-HP, Hôpital Saint-Antoine, Paris, France
| | - Pierre-Marie Girard
- Inserm UMR_S1136, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France.,Department of Infectious Diseases, APHP, Hôpital Saint-Antoine, Paris, France
| | - Jacqueline Capeau
- Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN, Paris, France
| | | |
Collapse
|
20
|
Gorlier C, Sellam J, Laurans L, Simon T, Giurgea I, Bastard JP, Fellahi S, Deshayes S, Grateau G, Ait Oufella H, Georgin-Lavialle S. In familial Mediterranean fever, soluble TREM-1 plasma level is higher in case of amyloidosis. Innate Immun 2019; 25:487-490. [PMID: 31474164 PMCID: PMC6900667 DOI: 10.1177/1753425919870847] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We aimed to explore triggering receptor expressed on myeloid cells-1 (TREM-1)
activation in familial Mediterranean fever (FMF), the most frequent monogenic
auto-inflammatory disease, through the measurement of its serum soluble form,
named sTREM-1. Blood samples from patients with FMF according to Livneh criteria
followed in the French FMF national center and carrying two pathogenic
MEFV mutations were collected. Serum level of sTREM-1 was
assessed using ELISA. Demographic data, presence of FMF attack, association with
histologically proven AA amyloidosis, and blood levels of C-reactive protein
(CRP), serum amyloid A (SAA) protein, and creatinine were collected. TREM-1 was
available in 56 patients (33.9% male, mean age 43 yr); AA amyloidosis was
associated in six patients (19.6% in FMF). Mean sTREM-1 level did not differ
significantly between patients having an attack or not and there was also no
significant correlation between the level of sTREM-1 and CRP and SAA protein.
However, the mean rate of sTREM-1 was significantly higher among FMF patients
with AA amyloidosis versus without, though the concomitant SAA protein level was
normal. Serum level of sTREM-1 was higher in patients with amyloidosis even
though the concomitant SAA protein level was normal. sTREM-1 plasma levels could
be an accurate tool to specifically identify FMF patients with amyloidosis.
Collapse
Affiliation(s)
- Clémence Gorlier
- Rheumatology Department, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, France
| | - Jérémie Sellam
- Rheumatology Department, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, France
| | - Ludivine Laurans
- Inserm U970, Paris Cardiovascular Research Center, Université René Descartes, France
| | - Tabassome Simon
- Plateforme de Recherche Clinique de l'Est Parisien (URCEST-CRCEST-CRB), AP-HP, Saint-Antoine Hospital, France
| | - Irina Giurgea
- Département de Génétique médicale, AP-HP, Hôpital Trousseau, Paris, France
| | | | - Soraya Fellahi
- Département de Biochimie, AP-HP, Hôpital Tenon, Paris, France
| | - Samuel Deshayes
- Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), AP-HP, Hôpital Tenon, Paris, France.,Service de médecine interne, UNICAEN, CHU de Caen Normandie, France
| | - Gilles Grateau
- Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), AP-HP, Hôpital Tenon, Paris, France
| | - Hafid Ait Oufella
- Inserm U970, Paris Cardiovascular Research Center, Université René Descartes, France.,Service de Réanimation-Médecine intensive, AP-HP, Hôpital Saint-Antoine, Paris, France
| | - Sophie Georgin-Lavialle
- Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), AP-HP, Hôpital Tenon, Paris, France
| |
Collapse
|
21
|
Deshayes S, Fellahi S, Bastard JP, Launay JM, Callebert J, Fraisse T, Buob D, Boffa JJ, Giurgea I, Dupont C, Jegou S, Straube M, Karras A, Aouba A, Grateau G, Sokol H, Georgin-Lavialle S. Specific changes in faecal microbiota are associated with familial Mediterranean fever. Ann Rheum Dis 2019; 78:1398-1404. [PMID: 31377728 DOI: 10.1136/annrheumdis-2019-215258] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 07/13/2019] [Accepted: 07/18/2019] [Indexed: 12/27/2022]
Abstract
OBJECTIVES Familial Mediterranean fever (FMF) can be complicated by AA amyloidosis (AAA), though it remains unclear why only some patients develop amyloidosis. We examined the gut microbiota composition and inflammatory markers in patients with FMF complicated or not by AAA. METHODS We analysed the gut microbiota of 34 patients with FMF without AAA, 7 patients with FMF with AAA, 19 patients with AAA of another origin, and 26 controls using 16S ribosomal RNA gene sequencing with the Illumina MiSeq platform. Associations between bacterial taxa and clinical phenotypes were evaluated using multivariate association with linear models statistical method. Blood levels of interleukin (IL)-1β, IL-6, tumour necrosis factor-α and adipokines were assessed by ELISA; indoleamine 2,3-dioxygenase (IDO) activity was determined by high-performance liquid chromatography. RESULTS Compared with healthy subjects, specific changes in faecal microbiota were observed in FMF and AAA groups. Several operational taxonomic units (OTUs) were associated with FMF. Moreover, two OTUs were over-represented in FMF-related AAA compared with FMF without AAA. Additionally, higher adiponectin levels and IDO activity were observed in FMF-related AAA compared with FMF without AAA (p<0.05). CONCLUSION The presence of specific changes in faecal microbiota in FMF and in FMF-related AAA suggests that intestinal microorganisms may play a role in the pathogenesis of these diseases. These findings may offer an opportunity to use techniques for gut microbiota manipulation.
Collapse
Affiliation(s)
- Samuel Deshayes
- Service de Médecine Interne, Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France.,Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.,Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France
| | - Soraya Fellahi
- UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.,Centre de Recherche Saint-Antoine, IHU ICAN, Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS 938, Paris, France
| | - Jean-Philippe Bastard
- UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.,Centre de Recherche Saint-Antoine, IHU ICAN, Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS 938, Paris, France
| | - Jean-Marie Launay
- Service de Biochimie, INSERM UMR S942, Assistance Publique des Hôpitaux de Paris, Hôpital Lariboisière, Paris, France
| | - Jacques Callebert
- Service de Biochimie, INSERM UMR S942, Assistance Publique des Hôpitaux de Paris, Hôpital Lariboisière, Paris, France
| | - Thibault Fraisse
- Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - David Buob
- Service d'Anatomopathologie, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - Jean-Jacques Boffa
- INSERM 1155, Sorbonne Université, AP-HP, Hôpital Tenon, F-75020 Paris, France
| | - Irina Giurgea
- Service de Génétique Médicale, Assistance Publique des Hôpitaux de Paris, Hôpital Trousseau, Paris, France
| | - Charlotte Dupont
- INSERM équipe Lipodystrophies génétiques et acquises. Service de biologiede la reproduction-CECOS, Sorbonne Université, Saint Antoine Research Center, AP-HP, Hôpital Tenon, F-75020 Paris, France
| | - Sarah Jegou
- Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France
| | - Marjolène Straube
- Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France
| | - Alexandre Karras
- Service de Néphrologie, Assistance Publique des Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Achille Aouba
- Service de Médecine Interne, Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - Gilles Grateau
- Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - Harry Sokol
- Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France .,MICALIS Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.,Service de Gastroentérologie, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France
| | - Sophie Georgin-Lavialle
- Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | | | | |
Collapse
|
22
|
Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open 2019; 5:e000897. [PMID: 31413865 PMCID: PMC6667971 DOI: 10.1136/rmdopen-2019-000897] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Revised: 03/28/2019] [Accepted: 04/15/2019] [Indexed: 12/17/2022] Open
Abstract
Background To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA). Methods We evaluated the serum levels of lipoprotein-associated apoproteins ApoA1 and ApoB100 and lipoprotein(a) (Lp(a)) and the leptin/adiponectin ratio (LAR) as an insulin resistance proxy in patients with RA from the Rotation Or Change (ROC) trial treated with either a second-line TNFi or another biologic (tocilizumab (TCZ), rituximab or abatacept) at baseline and week 24. We compared the changes in biomarker levels in each group and according to the EULAR response. Results Of the 300 patients enrolled in the ROC trial, 203 were included in the study, including 96 in the second-line TNFi group and 107 in the other biological group. The measured biomarkers did not deteriorate between baseline and week 24 regardless of the group. A greater improvement in the LAR was noted in the other biological group (median (IQR) -0.12 ng/µg (-0.58 to 0.31) vs 0.04 (-0.19 to 0.43), p=0.033), and a greater improvement in the Lp(a) level was observed following treatment with TCZ than with a TNFi (-0.05 g/L (-0.11 to -0.01) vs -0.01 g/L (-0.02 to 0.01), p<0.001). When considering the patients' responses to treatment, improved biomarkers were mainly observed in the EULAR responders in each treatment group. Conclusions TNFis and non-TNFis were neutral on improved CVD risk-associated biomarkers in patients with RA insufficiently controlled by TNFis. TCZ could be associated with a better improvement concerning Lp(a) and LAR than TNFis. This improvement could be related to a good therapeutic response, thereby supporting the need of good control of RA. Trial registration number ClinicalTrials.gov Identifier NCT01000441, registered on 22 October 2009.
Collapse
Affiliation(s)
- Alexandre Virone
- Rheumatology Department, Hôpital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France
| | - Jean-Philippe Bastard
- Biochemistry Department, Hôpital Tenon, AP-HP, Paris, France.,Faculty of Medicine Sorbonne Université, CRSA INSERM UMRS_938, Paris, France
| | - Soraya Fellahi
- Biochemistry Department, Hôpital Tenon, AP-HP, Paris, France.,Faculty of Medicine Sorbonne Université, CRSA INSERM UMRS_938, Paris, France
| | - Jacqueline Capeau
- Faculty of Medicine Sorbonne Université, CRSA INSERM UMRS_938, Paris, France
| | | | - Jean Sibilia
- Rheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Philippe Ravaud
- Epidemiology and Statistics Research Centre, Inserm UMR 1153, Paris Descartes University, Paris, France
| | - Francis Berenbaum
- Rheumatology Department, Hôpital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France.,Faculty of Medicine Sorbonne Université, CRSA INSERM UMRS_938, Paris, France
| | | | - Jérémie Sellam
- Rheumatology Department, Hôpital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France.,Faculty of Medicine Sorbonne Université, CRSA INSERM UMRS_938, Paris, France
| |
Collapse
|
23
|
Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, Boccara F, Capeau J. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf 2019; 18:829-840. [PMID: 31304808 DOI: 10.1080/14740338.2019.1644317] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Introduction: Efficient antiretroviral-treatment (ART) generally allows control of HIV infection. However, persons-living-with-HIV (PLWH), when aging, present a high prevalence of metabolic diseases. Area covered: Altered adiposity, dyslipidemias, insulin resistance, diabetes, and their consequences are prevalent in PLWH and could be partly related to ART. Expert opinion: At first, personal and lifestyle factors are involved in the onset of these complications. The persistence of HIV in tissue reservoirs could synergize with some ART and enhance metabolic disorders. Altered fat repartition, diagnosed as lipodystrophy, has been related to first-generation nucleoside-reverse-transcriptase-inhibitors (NRTIs) (stavudine zidovudine) and some protease inhibitors (PIs). Recently, use of some integrase-inhibitors (INSTI) resulted in weight/fat gain, which represents a worrisome unresolved situation. Lipid parameters were affected by some first-generation NRTIs, non-NRTIs (efavirenz) but also PIs boosted by ritonavir, with increased total and LDL-cholesterol and triglycerides. Insulin resistance is common associated with abdominal obesity. Diabetes incidence, high with first-generation-ART (zidovudine, stavudine, didanosine, indinavir) has declined with contemporary ART close to that of the general population. Metabolic syndrome, a dysmetabolic situation with central obesity and insulin resistance, and liver steatosis are common in PLWH and could indirectly result from ART-associated fat gain and insulin resistance. All these dysmetabolic situations increase the atherogenic cardiovascular risk.
Collapse
Affiliation(s)
- Claire Lagathu
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France
| | - Véronique Béréziat
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France
| | - Jennifer Gorwood
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France
| | - Soraya Fellahi
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France.,b Department of Biochemistry, APHP, Hôpital Tenon , Paris , France
| | - Jean-Philippe Bastard
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France.,b Department of Biochemistry, APHP, Hôpital Tenon , Paris , France
| | - Corinne Vigouroux
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France.,c Centre de Référence des Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité (PRISIS), Laboratoire Commun de Biologie et Génétique Moléculaires, APHP, Hôpital Saint-Antoine , Paris , France
| | - Franck Boccara
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France.,d Department of Cardiology, APHP Hôpital Saint-Antoine , Paris , France
| | - Jacqueline Capeau
- a Faculty of Medicine, Sorbonne Université, Inserm UMR_S938, ICAN , Paris , France
| |
Collapse
|
24
|
Bastard JP, Fellahi S, Regeniter A, Capeau J, Ronco P, Plaisier E. Aside from acute renal failure cases, are urinary markers of glomerular and tubular function useful in clinical practice? Clin Biochem 2019; 65:1-6. [PMID: 30685208 DOI: 10.1016/j.clinbiochem.2019.01.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 01/22/2019] [Accepted: 01/24/2019] [Indexed: 12/20/2022]
Abstract
The qualitative evaluation of proteinuria represents a crucial diagnostic step in clinical practice for the classification of renal diseases according to glomerular, tubulo-interstitial, mixed injury or related to monoclonal gammopathy. Combined with the quantitative evaluation, it also allows an assessment of the disease's severity and prognosis as well as the response to treatment. The development of the urine protein profile (UPP) combines specific urine protein assays on a urine spot analyzing glomerular protein markers such as albumin, transferrin and immunoglobulin G, and tubular markers such as alpha-1microglobulin and retinol binding protein, to generate a detailed quantitative and qualitative proteinuria assessment. This short overview proposes to illustrate the diagnostic and prognostic usefulness of UPP in different common clinical situations.
Collapse
Affiliation(s)
- Jean-Philippe Bastard
- AP-HP, UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Hôpital Tenon, Paris, France; Sorbonne Université, UPMC Université Paris 06, INSERM UMRS_938, CDR-Saint-Antoine, DHU i2B, IHU ICAN, Paris, France.
| | - Soraya Fellahi
- AP-HP, UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Hôpital Tenon, Paris, France; Sorbonne Université, UPMC Université Paris 06, INSERM UMRS_938, CDR-Saint-Antoine, DHU i2B, IHU ICAN, Paris, France
| | - Axel Regeniter
- Medica medical Laboratories, Wolfbachstrasse 17, CH-8032 Zurich, Switzerland
| | - Jacqueline Capeau
- Sorbonne Université, UPMC Université Paris 06, INSERM UMRS_938, CDR-Saint-Antoine, IHU ICAN, Paris, France
| | - Pierre Ronco
- Sorbonne Université, UPMC Université Paris 06, INSERM UMRS_1155, Paris, France.; AP-HP, Service de Néphrologie et Dialyse, Hôpital Tenon, Paris, France
| | - Emmanuelle Plaisier
- Sorbonne Université, UPMC Université Paris 06, INSERM UMRS_1155, Paris, France.; AP-HP, Service de Néphrologie et Dialyse, Hôpital Tenon, Paris, France
| |
Collapse
|
25
|
Nicolas A, Mohammedi K, Bastard JP, Fellahi S, Bellili-Muñoz N, Roussel R, Hadjadj S, Marre M, Velho G, Fumeron F. T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. Nephrol Dial Transplant 2018; 32:1987-1993. [PMID: 28499019 DOI: 10.1093/ndt/gfx071] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Accepted: 03/16/2017] [Indexed: 01/08/2023] Open
Abstract
Background High plasma adiponectin levels are associated with diabetic nephropathy (DN). T-cadherin gene (CDH13) variants have been shown to be associated with adiponectin levels. We investigated associations between allelic variations of CDH13 and DN in subjects with type 1 diabetes. Methods Two CDH13 polymorphisms were analysed in 1297 Caucasian subjects with type 1 diabetes from the 'Survival Genetic Nephropathy' (SURGENE) (n = 340, 10-year follow-up), 'Genesis France-Belgium' (GENESIS) (n = 501, 5-year follow-up for n = 462) and 'Génétique de la Néphropathie Diabétique' (GENEDIAB) (n = 456, 9-year follow-up for n = 283) cohorts. Adiponectin levels were measured in plasma samples from GENESIS and GENEDIAB cohorts. Results Pooled analysis of GENEDIAB and GENESIS studies showed that baseline plasma adiponectin levels were higher in subjects with established/advanced DN at inclusion (P < 0.0001) and in subjects who developed end-stage renal disease (ESRD) at follow-up (P < 0.0001). The minor allele of rs3865188 was associated with lower adiponectin levels (P = 0.006). rs11646213 [odds ratio (OR) 1.47; 95% confidence interval (CI) 1.18-1.85; P = 0.0009] and rs3865188 (OR 0.71; 95% CI 0.57-0.90; P = 0.004) were associated with baseline prevalence of established/advanced DN. These polymorphisms were also associated with the risk of ESRD (0.006 < P < 0.03). The association between rs11646213 (but not rs3865188) and renal function remained significant after adjustment for plasma adiponectin. In SURGENE, rs11646213 [hazard ratio (HR) 1.69; 95% CI 1.01-2.71; P = 0.04] and rs3865188 (HR 0.74; 95% CI 0.55-0.99; P = 0.04) were associated with risk of renal events (defined as progression to more severe DN stages). Conclusions Plasma adiponectin levels are associated with the prevalence of DN and the incidence of ESRD in patients with type 1 diabetes. CDH13 polymorphisms are also associated with the prevalence and incidence of DN, and with the incidence of ESRD in these patients. The association between CDH13 and DN may be due to pleiotropic effects, both dependent and independent of plasma adiponectin levels.
Collapse
Affiliation(s)
- Anthony Nicolas
- INSERM, UMR-S 1138, Centre de Recherches des Cordeliers, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR-S 1138, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
| | - Kamel Mohammedi
- INSERM, UMR-S 1138, Centre de Recherches des Cordeliers, Paris, France.,Univ Paris Diderot, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.,Department of Diabetology, Endocrinology and Nutrition, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Philippe Bastard
- Biochemistry and Hormonology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Soraya Fellahi
- Biochemistry and Hormonology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Ronan Roussel
- INSERM, UMR-S 1138, Centre de Recherches des Cordeliers, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR-S 1138, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.,Univ Paris Diderot, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.,Department of Diabetology, Endocrinology and Nutrition, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Samy Hadjadj
- Université de Poitiers, UFR Médecine Pharmacie, CIC1402, Poitiers, France.,Department of Diabetology and Endocrinology, Pole DUNE & Centre d'investigation clinique, University Hospital, Poitiers, France.,INSERM, CIC1402, Poitiers, France
| | - Michel Marre
- INSERM, UMR-S 1138, Centre de Recherches des Cordeliers, Paris, France.,Univ Paris Diderot, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.,Department of Diabetology, Endocrinology and Nutrition, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gilberto Velho
- INSERM, UMR-S 1138, Centre de Recherches des Cordeliers, Paris, France
| | - Frédéric Fumeron
- INSERM, UMR-S 1138, Centre de Recherches des Cordeliers, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR-S 1138, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.,Univ Paris Diderot, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
26
|
Chabot K, Lavoie ME, Bastard JP, Rabasa-Lhoret R. Intravenous catheters induce a local inflammatory response. Cytokine 2018; 111:470-474. [PMID: 29903592 DOI: 10.1016/j.cyto.2018.05.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2017] [Revised: 04/13/2018] [Accepted: 05/29/2018] [Indexed: 12/27/2022]
Abstract
AIM Chronic inflammation has been associated to the development of cardiometabolic dysfunctions. The use of an intravenous (IV) catheter is highly recommended for physiology testing. Yet, the presence of an IV catheter triggers local inflammation that does not reflect systemic inflammatory status. The aim of this study was to assess the effect of an IV catheter on serum concentrations of IL-6, IL-8 and hsCRP in a fasting state and after a high-fat meal known to trigger low-grade inflammation. METHODS Twenty-two healthy subjects (7 men, 15 women) were included in this study. The trial included 2 visits. After an overnight fast, a venous catheter was inserted into an antecubital vein. A first blood sample was collected through this catheter at T = 0 min. On each visit, participants were requested either to drink only water for the whole duration of the test (WO test), or to consume a high-fat meal (HFM). Blood samples were collected through the catheter at T60, T120, T180 and T300 min. Additional venous punctures were performed on the contralateral arm at T180 and T300 min. Serum inflammatory mediators were measured at each time point of both interventions. RESULTS When serum was collected by venous punctures, IL-6 concentrations remained unchanged during both WO and HFM tests (Ptime = 0.15 and Ptime = 0.23, respectively), whereas the concentrations increased progressively over time when serum was collected through the catheter (Ptime < 0.001). The high-fat meal had no additional effect on IL-6 levels (Pmeal = 0.27) neither in serum collected by venous puncture nor in serum collected through the catheter. Serum IL-8 and hsCRP concentrations did not vary over time, and were influenced neither by the meal type nor by the blood collection method. CONCLUSION The insertion of an indwelling catheter is associated with a local inflammatory response possibly mediated by IL-6 but not IL-8. This inflammatory response was not enhanced by a pro-inflammatory high-fat meal.
Collapse
Affiliation(s)
- Katherine Chabot
- Institut de recherches cliniques de Montréal (affiliated to the Université de Montréal), 110 Avenue des Pins Ouest, Montréal, QC H2W 1R7, Canada
| | - Marie-Eve Lavoie
- Department of Nutrition, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada; Institut de recherches cliniques de Montréal (affiliated to the Université de Montréal), 110 Avenue des Pins Ouest, Montréal, QC H2W 1R7, Canada
| | - Jean-Philippe Bastard
- AP-HP, Hôpital Tenon, UF Bio-marqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Paris F75020, France; Sorbonne Universities UPMC Paris 6, UMR_S 938 CDR-Saint-Antoine, F-75012 Paris, France; University Hospital ICAN Institute, Paris, France
| | - Rémi Rabasa-Lhoret
- Department of Nutrition, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada; Institut de recherches cliniques de Montréal (affiliated to the Université de Montréal), 110 Avenue des Pins Ouest, Montréal, QC H2W 1R7, Canada.
| |
Collapse
|
27
|
Elfassy Y, Bastard JP, McAvoy C, Fellahi S, Dupont J, Levy R. Adipokines in Semen: Physiopathology and Effects on Spermatozoas. Int J Endocrinol 2018; 2018:3906490. [PMID: 29971101 PMCID: PMC6008818 DOI: 10.1155/2018/3906490] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 03/07/2018] [Accepted: 03/19/2018] [Indexed: 12/14/2022] Open
Abstract
Adipokines are secreted by adipose tissue and could be the link between obesity and infertility. Different studies investigated the involvement of adipokines in reproductive functions but only a few have looked into the male part. This review assesses adipokine functions on male reproductive parameters. Adiponectin seems to have a positive effect on sperm parameters, whereas other adipokines such as resistin or chemerin would have a rather deleterious effect on spermatogenesis. Semen parameters seem to be impacted when resistin and chemerin are increased: indeed, there is a decrease of sperm motility. Sperm morphology is improved when adiponectin is increased. The most studied adipokine, leptin, has a dual effect with a positive effect on sperm at physiological levels and a negative one for high seminal concentrations. Many semen parameters and fertility itself are disturbed according to semen adipokine levels, even if it is not the only interfering element. Taken together, adipokines are found in human and animal semen and most of them or their receptors are expressed in male genital tract. Although the pathophysiological role of adipokines in semen is not clearly elucidated, the adipokines could influence sperm functionality and could be potential biomarkers of male fertility.
Collapse
Affiliation(s)
- Yaelle Elfassy
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Biologie de la Reproduction, Université Pierre et Marie Curie Paris 6, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| | - Jean-Philippe Bastard
- Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Paris, France
| | - Chloe McAvoy
- Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| | - Soraya Fellahi
- Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, Paris, France
| | - Joëlle Dupont
- INRA, UMR85, Physiologie de la Reproduction et des Comportements, Nouzilly, France
| | - Rachel Levy
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Biologie de la Reproduction, Université Pierre et Marie Curie Paris 6, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS_938, Centre de Recherche Saint-Antoine, IHU ICAN, Paris, France
| |
Collapse
|
28
|
Nicolas A, Mohammedi K, Bastard JP, Fellahi S, Bellili-Muñoz N, Roussel R, Hadjadj S, Marre M, Velho G, Fumeron F. T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. Nephrol Dial Transplant 2017; 32:2144. [DOI: 10.1093/ndt/gfx290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Monneret D, Bastard JP. Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives. Eur Respir J 2017; 50:50/2/1701038. [DOI: 10.1183/13993003.01038-2017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Accepted: 05/24/2017] [Indexed: 11/05/2022]
|
30
|
Elisha B, Disse E, Chabot K, Taleb N, Prud'homme D, Bernard S, Rabasa-Lhoret R, Bastard JP. Relative contribution of muscle and liver insulin resistance to dysglycemia in postmenopausal overweight and obese women: A MONET group study. Ann Endocrinol (Paris) 2016; 78:1-8. [PMID: 27931981 DOI: 10.1016/j.ando.2016.10.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 09/21/2016] [Accepted: 10/19/2016] [Indexed: 10/20/2022]
Abstract
OBJECTIVES The relative contribution of muscle and liver insulin resistance (IR) in the development of dysglycemia and metabolic abnormalities is difficult to establish. The present study aimed to investigate the relative contribution of muscle IR vs. liver IR to dysglycemia in non-diabetic overweight or obese postmenopausal women and to determine differences in body composition and cardiometabolic indicators associated with hepatic or muscle IR. MATERIAL AND METHODS Secondary analysis of 156 non-diabetic overweight or obese postmenopausal women. Glucose tolerance was measured using an oral glucose tolerance test. Whole-body insulin sensitivity (IS) was determined as glucose disposal rate during a euglycemic-hyperinsulinemic clamp. Muscle and liver IR have been calculated using Abdul-Ghani et al. OGTT-derived formulas. Participant's body compositions as well as cardiometabolic risk indicators were also determined. RESULTS Overall, 57 (36.5%) of patients had dysglycemia, among them 25 (16.0%); 21 (13.5%); 11 (7.1%) had impaired fasting glycemia, impaired glucose tolerance and combined glucose intolerance respectively. Fifty-three (34.0%) participants were classified as combined IS while on the opposite 51 participants (32.7%) were classified as combined IR and 26 (16.7%) participants had either muscle IR or liver IR. For similar body mass index and total fat mass, participants with liver IR were more likely to have lower whole-body IS, dysglycemia and higher visceral fat, liver fat index, triglycerides and alanine aminotransferase than participants with muscle IR. CONCLUSION In the present study, the presence of liver IR is associated with a higher prevalence of dysglycemia, ectopic fat accumulation and metabolic abnormalities than muscle IR.
Collapse
Affiliation(s)
- Belinda Elisha
- Department of Nutrition, Université de Montréal, Montréal, Québec, Canada; Department of Medicine, Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Emmanuel Disse
- Centre de Recherche en Nutrition Humaine, Rhône Alpes, Centre Hospitalier Lyon Sud, 69310 Pierre-Bénite, France
| | - Katherine Chabot
- Department of Nutrition, Université de Montréal, Montréal, Québec, Canada; Department of Medicine, Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Nadine Taleb
- Department of Nutrition, Université de Montréal, Montréal, Québec, Canada; Department of Medicine, Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Denis Prud'homme
- Institut de Recherche de l'Hôpital Montfort, Ottawa, Ontario, Canada; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada
| | - Sophie Bernard
- Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Rémi Rabasa-Lhoret
- Department of Nutrition, Université de Montréal, Montréal, Québec, Canada; Department of Medicine, Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Jean-Philippe Bastard
- Service de Biochimie et Hormonologie, AP-HP, Hôpital Tenon, UF Biomarqueurs Inflammatoires et Métaboliques, 75020 Paris, France; Inserm UMR_S938, ICAN, CDR Saint-Antoine, 75012 Paris, France; UMR_S 938, Sorbonne Universités, UPMC Université Paris 06, 75005 Paris, France.
| |
Collapse
|
31
|
Stankovic Stojanovic K, Hentgen V, Fellahi S, Georgin-Lavialle S, Amselem S, Grateau G, Bastard JP, Steichen O. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients. Clin Biochem 2016; 50:206-209. [PMID: 27838405 DOI: 10.1016/j.clinbiochem.2016.11.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 10/03/2016] [Accepted: 11/05/2016] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Monitoring SAA level in attack-free FMF patients is recommended in order to adjust colchicine dose, and minimize the risk of AA amyloidosis. In countries where this test is not available, C-reactive protein (CRP), another acute phase reactant, is used instead. However, CRP is low and SAA is increased in some patients and vice versa. OBJECTIVES To determine the threshold of CRP corresponding to SAA<10mg/L in patients with FMF and to assess their concordance at the patient level. PATIENTS AND METHODS Consecutive FMF patients in attack-free period and no other cause of intermittent inflammation including infections were recruited during their regular visits in the French reference center for FMF. Demographic and genetic data were recorded; CRP and SAA were tested simultaneously. The threshold value of CRP corresponding to 10mg/L for SAA was determined and the concordance between the two markers was assessed with Cohen's kappa index. RESULTS 399 samples were obtained from 218 patients, mean age of 27years (33% under 18years old), 55% of female, from Sephardic Jewish origin in 71%. MEFV mutation was M694V homozygous or compound heterozygous in 52%, and simple heterozygous in 18%. Six patients had AA amyloidosis. The appropriate CRP threshold was found to be 5mg/L in children and 8.75mg/L in adults. Global agreement with SAA<10mg/L was 84% [95% confidence interval: 82 to 86%], leading to a kappa index at 0.62 [95% confidence interval: 0.57 to 0.68]. CONCLUSION CRP<5mg/L in FMF children or 8.75mg/L in FMF adults during attack-free periods might be a convenient substitute to guide therapeutic decisions when SAA is unavailable.
Collapse
Affiliation(s)
- Katia Stankovic Stojanovic
- Assistance publique-hôpitaux de Paris, hôpital Tenon, Centre de référence adulte de la fièvre méditerranéenne familiale, service de médecine interne, F-75020 Paris, France; Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France.
| | - Véronique Hentgen
- Centre hospitalier de Versailles, centre de référence des maladies autoinflammatoires rares de l'enfant (CeRéMAI), service de pédiatrie, F-78150 Le Chesnay, France
| | - Soraya Fellahi
- Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France; Assistance publique-hôpitaux de Paris, hôpital Tenon, UF Bio-marqueurs inflammatoires et métaboliques, Service de biochimie, F-75020 Paris, France
| | - Sophie Georgin-Lavialle
- Assistance publique-hôpitaux de Paris, hôpital Tenon, Centre de référence adulte de la fièvre méditerranéenne familiale, service de médecine interne, F-75020 Paris, France; Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France; Sorbonne Université, UPMC université Paris 06, INSERM UMR_S933, F-75012 Paris, France
| | - Serge Amselem
- Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France; Sorbonne Université, UPMC université Paris 06, INSERM UMR_S933, F-75012 Paris, France; Assistance publique-hôpitaux de Paris, hôpital Armand-Trousseau, Centre de référence adulte de la fièvre méditerranéenne familiale, Laboratoire de génétique, F-75012 Paris, France
| | - Gilles Grateau
- Assistance publique-hôpitaux de Paris, hôpital Tenon, Centre de référence adulte de la fièvre méditerranéenne familiale, service de médecine interne, F-75020 Paris, France; Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France; Sorbonne Université, UPMC université Paris 06, INSERM UMR_S933, F-75012 Paris, France
| | - Jean-Philippe Bastard
- Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France; Assistance publique-hôpitaux de Paris, hôpital Tenon, UF Bio-marqueurs inflammatoires et métaboliques, Service de biochimie, F-75020 Paris, France
| | - Olivier Steichen
- Assistance publique-hôpitaux de Paris, hôpital Tenon, Centre de référence adulte de la fièvre méditerranéenne familiale, service de médecine interne, F-75020 Paris, France; Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France; Sorbonne Universités, UPMC Université Paris 06, INSERM, LIMICS, F-75005 Paris, France
| |
Collapse
|
32
|
Sellam J, Lacombe K, Tomi AL, Haugen IK, Felson DT, Fellahi S, Bastard JP, Miquel A, Sebire M, Rey-Jouvin C, Maheu E, Capeau J, Girard PM, Meynard JL, Berenbaum F. Response to: ‘Does the prevalence of radiographic hand osteoarthritis in patients with HIV-1 infection increase or not?’ by Luo et al. Ann Rheum Dis 2016; 75:e52. [DOI: 10.1136/annrheumdis-2016-209833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Accepted: 05/27/2016] [Indexed: 11/04/2022]
|
33
|
Tomi AL, Sellam J, Lacombe K, Fellahi S, Sebire M, Rey-Jouvin C, Miquel A, Bastard JP, Maheu E, Haugen IK, Felson DT, Capeau J, Girard PM, Berenbaum F, Meynard JL. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. Ann Rheum Dis 2016; 75:2101-2107. [PMID: 27034453 DOI: 10.1136/annrheumdis-2016-209262] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Revised: 02/23/2016] [Accepted: 03/12/2016] [Indexed: 01/05/2023]
Abstract
OBJECTIVE To determine radiographic hand osteoarthritis (HOA) prevalence in patients with HIV-1 infection in comparison with the general population and to address whether metabolic syndrome (MetS) may increase the risk of HOA during HIV-1 infection. PATIENTS Patients with HIV-1 infection and MetS (International Diabetes Federation, IDF criteria) aged 45-65 years were matched by age and gender to HIV-1-infected subjects without MetS and underwent hand radiographs. Framingham OA cohort was used as general population cohort. METHODS Radiographic HOA was defined as Kellgren-Lawrence (KL) score ≥2 on more than one joint. Radiographic severity was assessed by global KL score and number of OA joints. HOA prevalence was compared with that found in the Framingham study, stratified by age and sex. Logistic and linear regression models were used to determine the risk factors of HOA in patients with HIV-1 infection. RESULTS 301 patients (88% male, mean age 53.4±5.0 years) were included, 152 with MetS and 149 without it. Overall, HOA prevalence was 55.5% and was higher for those with MetS than those without it (64.5% vs 46.3%, p=0.002). When considering men within each age group, HOA frequency was greater in patients with HIV-1 infection than the general population (all ages: 55.8% vs 38.7%; p<0.0001), due to the subgroup with MetS (64.9%; p<0.0001), as well as the subgroup without MetS, although not significant (46.6%; p=0.09). Risk of HOA was increased with MetS (OR 2.23, 95% 95% CI 1.26% to 3.96%) and age (OR 1.18, 95% CI 1.12 to 1.25). HOA severity was greater for patients with MetS than those without. HOA was not associated with previous or current exposure to protease inhibitors or HIV infection-related markers. CONCLUSIONS HOA frequency is greater in patients with HIV-1 infection, especially those with MetS, than the general population. TRIAL REGISTRATION NUMBER NCT02353767.
Collapse
Affiliation(s)
- Anne-Laurence Tomi
- Department of Rheumatology, DHU i2B, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Department of Rheumatology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Jérémie Sellam
- Department of Rheumatology, DHU i2B, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Sorbonnes Universités, UPMC University Paris 06, INSERM UMRS_938, DHU i2B, Paris, France
| | - Karine Lacombe
- Sorbonnes Universités, UPMC University Paris 06, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.,Department of Infectious Diseases, Saint-Antoine Hospital, AP-HP, Paris, France
| | - Soraya Fellahi
- Sorbonnes Universités, UPMC University Paris 06, INSERM UMRS_938, DHU i2B, Paris, France.,Biochemistry Department, Tenon Hospital, AP-HP, Sorbonnes Universités, UPMC University Paris 06, INSERM UMR_S938, DHU i2B, IHU ICAN, Paris, France
| | - Manuela Sebire
- Department of Infectious Diseases, Saint-Antoine Hospital, AP-HP, Paris, France
| | - Caroline Rey-Jouvin
- Department of Rheumatology, DHU i2B, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Anne Miquel
- Department of Radiology, Saint-Antoine Hospital, AP-HP, Paris, France
| | - Jean-Philippe Bastard
- Sorbonnes Universités, UPMC University Paris 06, INSERM UMRS_938, DHU i2B, Paris, France.,Biochemistry Department, Tenon Hospital, AP-HP, Sorbonnes Universités, UPMC University Paris 06, INSERM UMR_S938, DHU i2B, IHU ICAN, Paris, France
| | - Emmanuel Maheu
- Department of Rheumatology, DHU i2B, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Ida K Haugen
- Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
| | - David T Felson
- Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA
| | - Jacqueline Capeau
- Sorbonnes Universités, UPMC University Paris 06, INSERM UMRS_938, DHU i2B, Paris, France.,Biochemistry Department, Tenon Hospital, AP-HP, Sorbonnes Universités, UPMC University Paris 06, INSERM UMR_S938, DHU i2B, IHU ICAN, Paris, France
| | - Pierre-Marie Girard
- Sorbonnes Universités, UPMC University Paris 06, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.,Department of Infectious Diseases, Saint-Antoine Hospital, AP-HP, Paris, France
| | - Francis Berenbaum
- Department of Rheumatology, DHU i2B, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,Sorbonnes Universités, UPMC University Paris 06, INSERM UMRS_938, DHU i2B, Paris, France
| | - Jean-Luc Meynard
- Department of Infectious Diseases, Saint-Antoine Hospital, AP-HP, Paris, France
| |
Collapse
|
34
|
Fève B, Bastard C, Fellahi S, Bastard JP, Capeau J. New adipokines. Ann Endocrinol (Paris) 2016; 77:49-56. [PMID: 26852251 DOI: 10.1016/j.ando.2016.01.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2015] [Revised: 12/22/2015] [Accepted: 01/06/2016] [Indexed: 01/23/2023]
Abstract
Adipose tissue is now widely recognized as "an organ" able to synthesize and secrete hundred factors collectively called adipokines. These secreted molecules exert pleiotropic actions, notably on the regulation of glucose and lipid metabolism, inflammation, reproduction, or angiogenesis. Over the past two decades, a considerable amount of work was performed on the two "star" adipokines, leptin and adiponectin, particularly because of their involvement in energy metabolism. The present review is focused on the three most recently discovered adipokines that are clearly emerging as important actors in metabolism: apelin, fibroblast growth factor-21, and neuroregulin-4. Moreover, given a number of clinical and experimental data, these three adipokines represent promising targets in the context of metabolic disorders associated with obesity.
Collapse
Affiliation(s)
- Bruno Fève
- UMR_S 938 CDR-Saint-Antoine, faculté de médecine, Sorbonne Universities UPMC Paris 6, 27, rue de Chaligny, 75012 Paris, France; University Hospital ICAN Institute, 75013 Paris, France; Endocrinology, Saint-Antoine Hospital, AP-HP, 75012 Paris, France.
| | - Claire Bastard
- Service de chirurgie digestive et viscérale, Centre hospitalier Sud Francilien, 91000 Corbeil-Essonnes, France
| | - Soraya Fellahi
- UMR_S 938 CDR-Saint-Antoine, faculté de médecine, Sorbonne Universities UPMC Paris 6, 27, rue de Chaligny, 75012 Paris, France; University Hospital ICAN Institute, 75013 Paris, France; Biochemistry Department, hôpital Tenon, AP-HP, 75020 Paris, France
| | - Jean-Philippe Bastard
- UMR_S 938 CDR-Saint-Antoine, faculté de médecine, Sorbonne Universities UPMC Paris 6, 27, rue de Chaligny, 75012 Paris, France; University Hospital ICAN Institute, 75013 Paris, France; Biochemistry Department, hôpital Tenon, AP-HP, 75020 Paris, France
| | - Jacqueline Capeau
- UMR_S 938 CDR-Saint-Antoine, faculté de médecine, Sorbonne Universities UPMC Paris 6, 27, rue de Chaligny, 75012 Paris, France; University Hospital ICAN Institute, 75013 Paris, France; Biochemistry Department, hôpital Tenon, AP-HP, 75020 Paris, France
| |
Collapse
|
35
|
Liu Y, Cotillard A, Vatier C, Bastard JP, Fellahi S, Stévant M, Allatif O, Langlois C, Bieuvelet S, Brochot A, Guilbot A, Clément K, Rizkalla SW. Correction: A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One 2015; 10:e0145315. [PMID: 26661459 PMCID: PMC4682837 DOI: 10.1371/journal.pone.0145315] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
36
|
Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gérard L, May T, Simon A, Vigouroux C, Goujard C. Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities. PLoS One 2015; 10:e0144317. [PMID: 26636578 PMCID: PMC4670073 DOI: 10.1371/journal.pone.0144317] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 11/15/2015] [Indexed: 11/18/2022] Open
Abstract
Objectives HIV-induced immunodeficiency is associated with metabolic abnormalities and systemic inflammation. We investigated the effect of antiretroviral therapy (ART) on restoration of insulin sensitivity, markers of immune activation and inflammation. Methods Immunological, metabolic and inflammatory status was assessed at antiretroviral therapy initiation and three years later in 208 patients from the ANRS-COPANA cohort. Patients were compared according to their pre-ART CD4+ cell count (group 1: ≤ 200/mm3, n = 66 vs. group 2: > 200/mm3, n = 142). Results Median CD4+ cell count increased in both groups after 3 years of successful ART but remained significantly lower in group 1 than in group 2 (404 vs 572 cells/mm3). Triglyceride and insulin levels were higher or tended to be higher in group 1 than in group 2 at ART initiation (median: 1.32 vs 0.97 mmol/l, p = 0.04 and 7.6 vs 6.8 IU, p = 0.09, respectively) and remained higher after three years of ART (1.42 vs 1.16 mmol/L, p = 0.0009 and 8.9 vs 7.2 IU, p = 0.01). After adjustment for individual characteristics and antiretroviral therapy regimens (protease inhibitor (PI), zidovudine), insulin levels remained significantly higher in patients with low baseline CD4+ cell count. Baseline IL-6, sCD14 and sTNFR2 levels were higher in group 1 than in group 2. Most biomarkers of immune activation/inflammation declined during ART, but IL-6 and hsCRP levels remained higher in patients with low baseline CD4+ cell count than in the other patients (median are respectively 1.4 vs 1.1 pg/ml, p = 0.03 and 2.1 vs 1.3 mg/ml, p = 0.07). Conclusion After three years of successful ART, low pretreatment CD4+ T cell count remained associated with elevated insulin, triglyceride, IL-6 and hsCRP levels. These persistent metabolic and inflammatory abnormalities could contribute to an increased risk of cardiovascular and metabolic disease.
Collapse
Affiliation(s)
- Mathilde Ghislain
- Inserm UMRS1018, CESP, Epidemiology of HIV and STI, Le Kremlin-Bicêtre, France
- * E-mail:
| | - Jean-Philippe Bastard
- Tenon Hospital, AP-HP, Department of Biochemistry and Hormonology, Paris, France
- Inserm UMRS 938, Centre de Recherche Saint-Antoine, Paris, France
- Sorbonne Universities, UPMC, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Laurence Meyer
- Inserm UMRS1018, CESP, Epidemiology of HIV and STI, Le Kremlin-Bicêtre, France
- Paris-Sud university, Le Kremlin-Bicêtre, France
- Bicêtre Hospital, AP-HP, Department of Public Health, Le Kremlin-Bicêtre, France
| | - Jacqueline Capeau
- Tenon Hospital, AP-HP, Department of Biochemistry and Hormonology, Paris, France
- Inserm UMRS 938, Centre de Recherche Saint-Antoine, Paris, France
- Sorbonne Universities, UPMC, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Soraya Fellahi
- Tenon Hospital, AP-HP, Department of Biochemistry and Hormonology, Paris, France
- Inserm UMRS 938, Centre de Recherche Saint-Antoine, Paris, France
- Sorbonne Universities, UPMC, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Laurence Gérard
- Saint-Louis Hospital, AP-HP, Department of Clinic Immunopathology, Paris, France
| | - Thierry May
- Teaching hospital of Nancy, Brabois Hospitals, Department of Infectious and Tropical Diseases, Vandoeuvre les Nancy, France
| | - Anne Simon
- Pitié-Salpétrière Hospital, AP-HP, Department of Internal Medicine and Clinical Immunology, Paris, France
| | - Corinne Vigouroux
- Inserm UMRS 938, Centre de Recherche Saint-Antoine, Paris, France
- Sorbonne Universities, UPMC, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
- Saint-Antoine Hospital, AP-HP, Common Laboratory of Biology and Molecular Genetics, Paris, France
| | - Cécile Goujard
- Inserm UMRS1018, CESP, Epidemiology of HIV and STI, Le Kremlin-Bicêtre, France
- Paris-Sud university, Le Kremlin-Bicêtre, France
- Bicêtre Hospital, AP-HP, Department of Internal Medicine, Le Kremlin-Bicêtre, France
| | | |
Collapse
|
37
|
Bastard C, Antuna-Puente B, Fellahi S, Capeau J, Bastard JP. Systemic Adiponectin Values in Humans Require Standardized Units. Obes Surg 2015; 26:381-2. [PMID: 26597846 DOI: 10.1007/s11695-015-1960-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Claire Bastard
- Service de chirurgie digestive et viscérale, Centre Hospitalier Sud Francilien, 91000, Corbeil-Essonnes, France.
| | - Barbara Antuna-Puente
- Laboratorio de Genómica de Enfermedades Cardiovasculares, Instituto Nacional de Medicina Genómica, Periférico Sur No.4809, 14610, Ciudad de México, Distrito Federal, Mexico.
| | - Soraya Fellahi
- UF Bio-marqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, AP-HP, Hôpital Tenon, 4 Rue de la Chine, F75020, Paris, France.
- Inserm UMR_S938, ICAN, CDR Saint-Antoine, F75012, Paris, France.
- UPMC Univ Paris 06, UMR_S 938, Sorbonne Universités, F75005, Paris, France.
| | - Jacqueline Capeau
- UF Bio-marqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, AP-HP, Hôpital Tenon, 4 Rue de la Chine, F75020, Paris, France.
- Inserm UMR_S938, ICAN, CDR Saint-Antoine, F75012, Paris, France.
- UPMC Univ Paris 06, UMR_S 938, Sorbonne Universités, F75005, Paris, France.
| | - Jean-Philippe Bastard
- UF Bio-marqueurs Inflammatoires et Métaboliques, Service de Biochimie et Hormonologie, AP-HP, Hôpital Tenon, 4 Rue de la Chine, F75020, Paris, France.
- Inserm UMR_S938, ICAN, CDR Saint-Antoine, F75012, Paris, France.
- UPMC Univ Paris 06, UMR_S 938, Sorbonne Universités, F75005, Paris, France.
| |
Collapse
|
38
|
Lemoine M, Chevaliez S, Bastard JP, Fartoux L, Chazouillères O, Capeau J, Pawlotsky JM, Serfaty L. Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance. J Viral Hepat 2015; 22:890-6. [PMID: 25818002 DOI: 10.1111/jvh.12408] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Accepted: 01/31/2015] [Indexed: 12/31/2022]
Abstract
TNFα has been shown to play a role in hepatitis C virus (HCV)-induced insulin resistance (IR). Polymorphism of the IL28B gene that encodes IFN-lambda 3 may be associated with IR through modulation of TNFα. The aim of this study was to investigate the relationship between IL28B rs12979860 genotype, the level of TNFα activation and the degree of IR in patients with chronic hepatitis C. One hundred and thirty-three nondiabetic genotype 1 HCV-infected patients with biopsy proven noncirrhotic hepatitis C were investigated for IR (using HOMA index), IL28B rs12979860 genotype and fasting circulating levels of soluble receptor 1 of TNFα (sTNFR1) and adipokines: leptin, adiponectin and IL-6. The HOMA-IR was positively correlated with serum levels of leptin (r = 0.35, P < 0.0001) and sTNFR1 (r = 0.35, P < 0.0001) but not with IL-6 or adiponectin. IL28B rs12979860 CC genotype was observed in 35% patients. Genotype CC and nongenotype CC patients were similar in terms of HOMA-IR (means 1.6 ± 0.9 vs 1.7 ± 1.4) and had similar circulating levels of sTNFR1 and adipokines. Independent factors associated with IR were ferritin (OR = 1.002, P = 0.02), leptin (OR = 1.06, P = 0.02) and sTNFR1 (OR = 7.9, P = 0.04). This study suggests that in nondiabetic, noncirrhotic, HCV genotype 1-infected patients, there is no relationship between IL28B rs12979860 genotype and HOMA-IR or sTNFR1 level. HCV-related IR may be mediated through TNFα independent of IL28B genotype.
Collapse
Affiliation(s)
- M Lemoine
- Service d'Hépatologie, APHP, Hôpital Saint-Antoine, Paris, France
- UPMC Université Paris 06, UMR_S938, Paris, France
| | - S Chevaliez
- APHP, Laboratoire de Virologie, Hopital Henri Mondor, Créteil, France
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - J P Bastard
- UPMC Université Paris 06, UMR_S938, Paris, France
- Service de biochimie et hormonologie, APHP, Hôpital Tenon, Paris, France
| | - L Fartoux
- Service d'Hépatologie, APHP, Hôpital Saint-Antoine, Paris, France
| | - O Chazouillères
- Service d'Hépatologie, APHP, Hôpital Saint-Antoine, Paris, France
| | - J Capeau
- UPMC Université Paris 06, UMR_S938, Paris, France
- Service de biochimie et hormonologie, APHP, Hôpital Tenon, Paris, France
| | - J M Pawlotsky
- APHP, Laboratoire de Virologie, Hopital Henri Mondor, Créteil, France
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - L Serfaty
- Service d'Hépatologie, APHP, Hôpital Saint-Antoine, Paris, France
- UPMC Université Paris 06, UMR_S938, Paris, France
| |
Collapse
|
39
|
Gerbaud L, Debost-Legrand A, Ly E, Bastard JP. Etre & Savoir: Assessment of a 9 years program of health education for 8-10 years old schoolchildren. Eur J Public Health 2015. [DOI: 10.1093/eurpub/ckv176.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Liu Y, Cotillard A, Vatier C, Bastard JP, Fellahi S, Stévant M, Allatif O, Langlois C, Bieuvelet S, Brochot A, Guilbot A, Clément K, Rizkalla SW. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One 2015; 10:e0138646. [PMID: 26406981 PMCID: PMC4583280 DOI: 10.1371/journal.pone.0138646] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Accepted: 08/31/2015] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Preventing or slowing the progression of prediabetes to diabetes is a major therapeutic issue. OBJECTIVES Our aim was to evaluate the effects of 4-month treatment with a dietary supplement containing cinnamon, chromium and carnosine in moderately obese or overweight pre-diabetic subjects, the primary outcome being change in fasting plasma glucose (FPG) level. Other parameters of plasma glucose homeostasis, lipid profile, adiposity and inflammatory markers were also assessed. METHODS In a randomized, double-blind, placebo-controlled study, 62 subjects with a FPG level ranging from 5.55 to 7 mmol/L and a body mass index ≥ 25 kg/m(2), unwilling to change their dietary and physical activity habits, were allocated to receive a 4-month treatment with either 1.2 g/day of the dietary supplement or placebo. Patients were followed up until 6 months post-randomization. RESULTS Four-month treatment with the dietary supplement decreased FPG compared to placebo (-0.24 ± 0.50 vs +0.12 ± 0.59 mmol/L, respectively, p = 0.02), without detectable significant changes in HbA1c. Insulin sensitivity markers, plasma insulin, plasma lipids and inflammatory markers did not differ between the treatment groups. Although there were no significant differences in changes in body weight and energy or macronutrient intakes between the two groups, fat-free mass (%) increased with the dietary supplement compared to placebo (p = 0.02). Subjects with a higher FPG level and a milder inflammatory state at baseline benefited most from the dietary supplement. CONCLUSIONS Four-month treatment with a dietary supplement containing cinnamon, chromium and carnosine decreased FPG and increased fat-free mass in overweight or obese pre-diabetic subjects. These beneficial effects might open up new avenues in the prevention of diabetes. TRIAL REGISTRATION ClinicalTrials.gov NCT01530685.
Collapse
Affiliation(s)
- Yuejun Liu
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- INSERM, UMR S U1166, Nutriomics, 75013, Paris, France
- Sorbonne University, Pierre and Marie Curie University, Paris 06, UMR_S 1166 I, Nutriomics Team, Paris, France
| | - Aurélie Cotillard
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- INSERM, UMR S U1166, Nutriomics, 75013, Paris, France
- Sorbonne University, Pierre and Marie Curie University, Paris 06, UMR_S 1166 I, Nutriomics Team, Paris, France
| | - Camille Vatier
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- INSERM, UMR S U1166, Nutriomics, 75013, Paris, France
| | - Jean-Philippe Bastard
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- Assistance Publique-Hôpitaux de Paris, Biochemistry and Hormonology Department, Tenon Hospital, 75970, Paris, France
| | - Soraya Fellahi
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- Assistance Publique-Hôpitaux de Paris, Biochemistry and Hormonology Department, Tenon Hospital, 75970, Paris, France
| | | | - Omran Allatif
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- INSERM, UMR S U1166, Nutriomics, 75013, Paris, France
| | | | | | | | | | - Karine Clément
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- INSERM, UMR S U1166, Nutriomics, 75013, Paris, France
- Sorbonne University, Pierre and Marie Curie University, Paris 06, UMR_S 1166 I, Nutriomics Team, Paris, France
| | - Salwa W. Rizkalla
- Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France
- INSERM, UMR S U1166, Nutriomics, 75013, Paris, France
- Sorbonne University, Pierre and Marie Curie University, Paris 06, UMR_S 1166 I, Nutriomics Team, Paris, France
| |
Collapse
|
41
|
Lacroix D, Moutel S, Coupaye M, Huvenne H, Faucher P, Pelloux V, Rouault C, Bastard JP, Cagnard N, Dubern B, Clément K, Poitou C. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity. J Clin Endocrinol Metab 2015; 100:850-9. [PMID: 25478934 DOI: 10.1210/jc.2014-3127] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Prader-Willi syndrome (PWS), the most frequent syndrome of obesity, is a model of early fat mass (FM) development, but scarce data exist on adipose tissue characteristics. OBJECTIVE The objective of the study was to compare metabolic, fat distribution, and transcriptomic signatures of sc adipose tissue (scAT) in PWS adults, with matched obese adults with primary obesities. MAIN OUTCOMES AND MEASURES Hormonal and metabolic assessments, systemic inflammation, and gene expression in scAT were compared between PWS patients and obese controls (OCs). Each 42nd PWS patient was matched with one randomly paired control with primary obesity. Matching factors were age, gender, fat mass (percentage), and diabetic status. RESULTS Compared with OCs, the PWS group had a decreased percentage of trunk FM and a better metabolic profile with decreased insulin and homeostasis model assessment, an index of insulin-resistance, and increased concentrations of serum adiponectin and ghrelin. Adipocyte size relative to body fat was significantly higher in PWS vs OCs. scAT in PWS patients was characterized by a transcriptomic functional signature with enrichment of themes related to immunoinflammation, the extracellular matrix, and angiogenesis. A RT-PCR targeted study revealed that candidate genes encoding proinflammatory markers and remodeling molecules, CD68, CD3e, IL-1β, chemokine (C-C motif) ligand 5, collagen type 4-α, and lysyl oxidase, were down-regulated. CONCLUSION Matched for FM, PWS subjects have a better metabolic profile, a phenotype that could be linked to changes in scAT remodeling and promotion of adipocyte growth.
Collapse
Affiliation(s)
- Delphine Lacroix
- INSERM, U1166, Nutriomic team 6 (D.L., H.H., V.P., C.R., B.D., K.C., C.P.), Sorbonne Universities (D.L., H.H., V.P., C.R., B.D., K.C., C.P.), University Pierre et Marie Curie-Paris 6, Unité Mixte de Recherche en Santé Unité 1166, and Institute of Cardiometabolism and Nutrition (ICAN) (S.M., M.C., P.F., K.C., C.P.), Assistance Publique Hôpitaux de Paris, Department of Nutrition, and French Reference Centre for Prader-Willi Syndrome, Pitié-Salpêtrière Hospital, Paris, F-75013 France; Functional Unit of Inflammatory and Metabolic Biomarkers (J.-P.B.), Department of Biochemistry and Hormonology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris, F-75970 Paris, France; Bioinformatics Platform (N.C.), Plateforme de Bioinformatique, SFR Necker, University Paris V, F-75015 Paris, France; and Department of Pediatric Nutrition and Gastroenterology (B.D.), Trousseau Hospital, Assistance Publique Hôpitaux de Paris, F-37044 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Bastard JP, Fellahi S, Couffignal C, Raffi F, Gras G, Hardel L, Sobel A, Leport C, Fardet L, Capeau J. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. J Antimicrob Chemother 2015; 70:1816-24. [PMID: 25733587 DOI: 10.1093/jac/dkv036] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 01/25/2015] [Indexed: 01/01/2023] Open
Abstract
OBJECTIVES The objective of this study was to analyse the respective roles of personal factors and HIV infection markers on the systemic immune activation/inflammatory profile of long-term antiretroviral treatment-controlled patients. PATIENTS AND METHODS A panel of soluble immune activation/inflammatory biomarkers was measured in 352 HIV-infected treatment-controlled patients from the APROCO-COPILOTE cohort, all of whom were started on a PI in 1997-99 and had a final evaluation 11 years later, and in 59 healthy controls. RESULTS A total of 81.5% of the patients were male, with the following characteristics: median age 49 years; 620 CD4 cells/mm(3); 756 CD8 cells/mm(3); CD4/CD8 ratio 0.81; BMI 23.0 kg/m(2); waist-to-hip ratio 0.95. Markers of inflammation-high-sensitivity (hs) IL-6 (median and IQR) (1.3 pg/L, 0.7-2.6), hs C-reactive protein (CRP) (2.1 mg/L, 0.9-4.5) and D-dimer (252 ng/mL, 177-374)-were elevated compared with healthy controls (P < 0.001) and strongly related to each other, as were markers of immune activation [soluble (s) CD14 (1356 ng/mL, 1027-1818), β2-microglobulin (2.4 mg/L, 2.0-3.1) and cystatin-C (0.93 mg/L, 0.82-1.1)]. Inflammatory and immune activation markers were also associated with each other. In HIV-infected patients: age was related to D-dimer, β2-microglobulin and cystatin-C levels; being a smoker was related to increased IL-6 and cystatin-C; and BMI and waist-to-hip ratio were related to CRP. Conversely, markers of HIV infection, current CD4 or CD8 values, CD4 nadir, CD4/CD8 ratio, AIDS stage at initiation of PIs, current viral load and duration of ART were not associated with immune activation/inflammation markers. CONCLUSIONS In these long-term treatment-controlled HIV-infected patients, all systemic markers of inflammation and immune activation were increased compared with healthy controls. This was related to demographic and behavioural factors, but not to markers of severity of the HIV infection. Intervention to decrease low-grade inflammation must thus prioritize modifiable personal factors.
Collapse
Affiliation(s)
- Jean-Philippe Bastard
- Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, APHP Hôpital Tenon and Saint-Antoine, 27 rue Chaligny, F-75571 Paris cedex 12, France
| | - Soraya Fellahi
- Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, APHP Hôpital Tenon and Saint-Antoine, 27 rue Chaligny, F-75571 Paris cedex 12, France
| | - Camille Couffignal
- IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité, Unité de Coordination du Risque Épidémique et Biologique, Assistance Publique-Hôpitaux de Paris, 16 rue Henri Huchard, F-75890 Paris cedex 18, France
| | | | - Guillaume Gras
- University Hospital of Tours, CHRU, F-37044 Tours cedex 9, France
| | - Lucile Hardel
- INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, 146 rue Léo Saignat, F-33076 Bordeaux cedex, France
| | - Alain Sobel
- Hotel-Dieu Hospital, 1 Parvis Notre-Dame, Place Jean-Paul II, F-75004 Paris, France
| | - Catherine Leport
- IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité, Unité de Coordination du Risque Épidémique et Biologique, Assistance Publique-Hôpitaux de Paris, 16 rue Henri Huchard, F-75890 Paris cedex 18, France
| | - Laurence Fardet
- Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, APHP Hôpital Tenon and Saint-Antoine, 27 rue Chaligny, F-75571 Paris cedex 12, France
| | - Jacqueline Capeau
- Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, APHP Hôpital Tenon and Saint-Antoine, 27 rue Chaligny, F-75571 Paris cedex 12, France
| | | |
Collapse
|
43
|
Bastard JP, Rabasa-Lhoret R, Laville M, Disse E. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Are there not some surrogate indexes lost in this story? Diabetologia 2015; 58:414-5. [PMID: 25341461 DOI: 10.1007/s00125-014-3424-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Accepted: 09/29/2014] [Indexed: 11/30/2022]
Affiliation(s)
- Jean-Philippe Bastard
- Service de Biochimie et Hormonologie, UF Bio-marqueurs Métaboliques et Inflammatoires, Hôpital Tenon, 4 rue de la Chine, 75970, Paris cedex 20, France,
| | | | | | | |
Collapse
|
44
|
Affiliation(s)
- Jean-Philippe Bastard
- AP-HP, Hôpital Tenon, Service de Biochimie et Hormonologie, Paris, France; INSERM UMR_S938, Centre de Recherche Saint-Antoine, Paris, France; and Université Pierre et Marie Curie Paris 06, UMR_S938, Paris, France
| | - Soraya Fellahi
- AP-HP, Hôpital Tenon, Service de Biochimie et Hormonologie, Paris, France; INSERM UMR_S938, Centre de Recherche Saint-Antoine, Paris, France; and Université Pierre et Marie Curie Paris 06, UMR_S938, Paris, France
| |
Collapse
|
45
|
Boyd A, Meynard JL, Morand-Joubert L, Michon A, Boccara F, Bastard JP, Samri A, Haddour N, Mallat Z, Capeau J, Desvarieux M, Girard PM. Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection. PLoS One 2014; 9:e113876. [PMID: 25415323 PMCID: PMC4240670 DOI: 10.1371/journal.pone.0113876] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Accepted: 10/08/2014] [Indexed: 11/26/2022] Open
Abstract
Background While residual plasma viremia is commonly observed in HIV-infected patients undergoing antiretroviral treatment (ART), little is known about its subclinical consequences. Methods This cross-sectional study included 47 male, never-smoking, non-diabetic patients with ≥4 years of ART and controlled HIV-replication (HIV-viral load, VL <20 copies/mL for ≥1 year). Residual HIV-VL was measured using an ultrasensitive assay (quantification limit: 1 copy/ml). Patients were categorized as having detectable (D; 1-20 copies/mL, n = 14) or undetectable (UD; <1 copies/mL, n = 33) HIV-VL. Linear regression was used to model the difference in total carotid intima-media thickness [c-IMT, measures averaged across common carotid artery (cca), bifurcation, and internal carotid artery] and cca-IMT alone across detection groups. Multivariable models were constructed for each endpoint in a forward-stepwise approach. Results No significant differences were observed between viremia groups with respect to median ART-duration (9.6 years, IQR = 6.8–10.9), nadir CD4+T-cell (208/mm3, IQR = 143–378), and CD4+T-cell count (555/mm3, IQR = 458–707). Median adjusted inflammatory markers tended to be higher in patients with D- than UD-viremia, with differences in IL-10 being significant (p = 0.03). After adjustment on age, systolic blood pressure, and insulin resistance, mean cca-IMT was significantly lower in patients with undetectable (0.668 mm±0.010) versus detectable viremia (0.727 mm±0.015, p = 0.002). Cca-IMT was also independently associated with age and insulin resistance. Mean adjusted total c-IMT was no different between viremia groups (p = 0.2), however there was large variability in bifurcation c-IMT measurements. Conclusions Higher cca-IMT was observed in patients with detectable, compared to undetectable, HIV-VL in never-smoking ART-controlled patients, suggesting that residual HIV viremia may be linked to atherosclerosis.
Collapse
Affiliation(s)
- Anders Boyd
- INSERM UMR_S 1136, Institut Pierre Louis d′Epidémiologie et de Santé Publique, Paris, France
- * E-mail:
| | - Jean-Luc Meynard
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- Department of Infectious and Tropical Diseases, Hôpital Saint-Antoine, AP-HP, Paris, France
| | - Laurence Morand-Joubert
- Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR_S 1136, Institut Pierre Louis d′Epidémiologie et de Santé Publique, Laboratoire de Virologie, Saint Antoine, APHP, Paris, France
| | - Adrien Michon
- Service de médecine interne, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - Franck Boccara
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- Department of Cardiology, Hôpital Saint-Antoine, AP-HP, Paris, France
- INSERM UMR_S 938, Paris, France
| | - Jean-Philippe Bastard
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- APHP, Hôpital Tenon, Service de biochimie et hormonologie, Inserm UMR_S938, and Institute of Cardiometabolism and Nutrition, Paris, France
| | - Assia Samri
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- Inserm, UMR-S945, IFR113, Department of Immunology, Paris, France
| | - Nabila Haddour
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- Department of Cardiology, Hôpital Saint-Antoine, AP-HP, Paris, France
| | - Ziad Mallat
- Inserm U970, Cardiovascular Research Center, and Université Paris-Descartes University, Paris, France
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Jacqueline Capeau
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- APHP, Hôpital Tenon, Service de biochimie et hormonologie, Inserm UMR_S938, and Institute of Cardiometabolism and Nutrition, Paris, France
| | - Moïse Desvarieux
- Department of Epidemiology, Columbia University, Mailman School of Public Health, New York, New York, United States of America
- Inserm U738 and Ecole des Hautes Études en Santé Publique, Paris, France
| | - Pierre-Marie Girard
- INSERM UMR_S 1136, Institut Pierre Louis d′Epidémiologie et de Santé Publique, Paris, France
- Sorbonne Université, UPMC Univ Paris-6, Paris, France
- Department of Infectious and Tropical Diseases, Hôpital Saint-Antoine, AP-HP, Paris, France
| | | |
Collapse
|
46
|
Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O, Lioté F, Simon T, Capeau J, Berenbaum F. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther 2014; 15:R210. [PMID: 24314299 PMCID: PMC3978925 DOI: 10.1186/ar4404] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Accepted: 11/21/2013] [Indexed: 12/15/2022] Open
Abstract
Introduction Adipokines such as adiponectin, leptin, and visfatin/nicotinamide phosphoribosyltransferase (NAMPT) have recently emerged as pro-inflammatory mediators involved in the pathophysiology of rheumatoid arthritis (RA). We aimed to determine whether serum adipokine levels independently predicted early radiographic disease progression in early RA. Methods In total, 791 patients were included from the prospective Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort who met the American College of Rheumatology-European League Against Rheumatism criteria for RA (n = 632) or had undifferentiated arthritis (UA) (n = 159). Enzyme-linked immunosorbent assay (ELISA) was used to assess baseline serum levels of adiponectin, leptin, and visfatin/NAMPT. In the RA group, we tested the association of serum adipokine levels and (a) baseline radiographic damage and (b) radiographic disease progression, defined as a change >0 or ≥5 in total Sharp-van der Heijde Score (∆SHS) between inclusion and 1 year (∆SHS ≥1 or rapid radiographic progression: ∆SHS ≥5), adjusting for confounders (age, sex, body-mass index, insulin resistance, C-reactive protein level, Disease Activity Score in 28 joints, Health Assessment Questionnaire score, autoantibody status, steroid use, and radiographic evidence of RA damage at inclusion). Results Adiponectin level was independently associated with baseline total SHS (adjusted β = 0.12; P = 0.006). It was also associated with ∆SHS ≥1 (adjusted odds ratio (aOR) = 1.84 (1.25 to 2.72)) involving erosive as well as narrowing disease progression (aOR = 1.73 (1.17 to 2.55) and 1.93 (1.04 to 3.57), respectively). Serum adiponectin level predicted ∆SHS ≥5 (aOR = 2.0 (1.14 to 3.52)). Serum leptin level was independently associated only with ∆SHS >0 (aOR = 1.59 (1.05 to 2.42)). Conversely, serum visfatin/NAMPT level and radiographic disease progression were unrelated. Considering the receiver-operated characteristic curves, the best adiponectin cut-offs were 4.14 μg/ml for ∆SHS ≥1 and 6.04 μg/ml for ∆SHS ≥5, with a good specificity (58% and 75% for ∆SHS ≥1 and ∆SHS ≥5, respectively) and high negative predictive values (75% and 92% for ∆SHS ≥1 or ∆SHS ≥5, respectively). Conclusion Serum adiponectin level is a simple useful biomarker associated with early radiographic disease progression in early RA, independent of RA-confounding factors and metabolic status.
Collapse
|
47
|
Kong LC, Holmes BA, Cotillard A, Habi-Rachedi F, Brazeilles R, Gougis S, Gausserès N, Cani PD, Fellahi S, Bastard JP, Kennedy SP, Doré J, Ehrlich SD, Zucker JD, Rizkalla SW, Clément K. Dietary patterns differently associate with inflammation and gut microbiota in overweight and obese subjects. PLoS One 2014; 9:e109434. [PMID: 25330000 PMCID: PMC4203727 DOI: 10.1371/journal.pone.0109434] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 09/04/2014] [Indexed: 01/22/2023] Open
Abstract
Background Associations between dietary patterns, metabolic and inflammatory markers and gut microbiota are yet to be elucidated. Objectives We aimed to characterize dietary patterns in overweight and obese subjects and evaluate the different dietary patterns in relation to metabolic and inflammatory variables as well as gut microbiota. Design Dietary patterns, plasma and adipose tissue markers, and gut microbiota were evaluated in a group of 45 overweight and obese subjects (6 men and 39 women). A group of 14 lean subjects were also evaluated as a reference group. Results Three clusters of dietary patterns were identified in overweight/obese subjects. Cluster 1 had the least healthy eating behavior (highest consumption of potatoes, confectionary and sugary drinks, and the lowest consumption of fruits that was associated also with low consumption of yogurt, and water). This dietary pattern was associated with the highest LDL cholesterol, plasma soluble CD14 (p = 0.01) a marker of systemic inflammation but the lowest accumulation of CD163+ macrophages with anti-inflammatory profile in adipose tissue (p = 0.05). Cluster 3 had the healthiest eating behavior (lower consumption of confectionary and sugary drinks, and highest consumption of fruits but also yogurts and soups). Subjects in this Cluster had the lowest inflammatory markers (sCD14) and the highest anti-inflammatory adipose tissue CD163+ macrophages. Dietary intakes, insulin sensitivity and some inflammatory markers (plasma IL6) in Cluster 3 were close to those of lean subjects. Cluster 2 was in-between clusters 1 and 3 in terms of healthfulness. The 7 gut microbiota groups measured by qPCR were similar across the clusters. However, the healthiest dietary cluster had the highest microbial gene richness, as evaluated by quantitative metagenomics. Conclusion A healthier dietary pattern was associated with lower inflammatory markers as well as greater gut microbiota richness in overweight and obese subjects. Trial Registration ClinicalTrials.gov NCT01314690
Collapse
Affiliation(s)
- Ling Chun Kong
- INSERM, UMR_S U1166, Nutriomics, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie-Paris, Paris, France
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Aurelie Cotillard
- INSERM, UMR_S U1166, Nutriomics, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie-Paris, Paris, France
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Rémi Brazeilles
- Danone Research, RD 128, Palaiseau, France
- IT&M STATS, Paris, France
| | - Sophie Gougis
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Patrice D. Cani
- Université catholique de Louvain, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOTechnology), Metabolism and Nutrition Research group, Brussels, Belgium
| | - Soraya Fellahi
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique Hôpitaux de Paris, Service de Biochimie et Hormonologie, Hôpital Tenon, Paris, France
| | - Jean-Philippe Bastard
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique Hôpitaux de Paris, Service de Biochimie et Hormonologie, Hôpital Tenon, Paris, France
| | - Sean P. Kennedy
- Institut National de la Recherche Agronomique, UMR 1319 MICALIS, Jouy en Josas, France
| | - Joel Doré
- Institut National de la Recherche Agronomique, UMR 1319 MICALIS, Jouy en Josas, France
| | | | - Jean-Daniel Zucker
- INSERM, UMR_S U1166, Nutriomics, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie-Paris, Paris, France
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
| | - Salwa W. Rizkalla
- INSERM, UMR_S U1166, Nutriomics, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie-Paris, Paris, France
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
- * E-mail:
| | - Karine Clément
- INSERM, UMR_S U1166, Nutriomics, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie-Paris, Paris, France
- Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Heart and Nutrition Department, and Human Nutrition Research Center-Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
| |
Collapse
|
48
|
Sellam J, Fellahi S, Bastard JP, Capeau J, Berenbaum F. Response to 'Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort' - authors' reply. Arthritis Res Ther 2014; 16:408. [PMID: 25166621 PMCID: PMC4060569 DOI: 10.1186/ar4538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
49
|
Laugerette F, Alligier M, Bastard JP, Drai J, Chanséaume E, Lambert-Porcheron S, Laville M, Morio B, Vidal H, Michalski MC. Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Mol Nutr Food Res 2014; 58:1513-8. [PMID: 24687809 DOI: 10.1002/mnfr.201400044] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Revised: 02/24/2014] [Accepted: 02/25/2014] [Indexed: 01/03/2023]
Abstract
SCOPE Low-grade inflammation is a recognized hallmark of obesity. Endotoxins absorbed after high-fat meals have recently been implicated. Plasma lipopolysaccharides binding protein (LBP) and soluble cluster of differentiation 14 (sCD14) have also been suggested as clinical markers of endotoxemia. In mice, the ratio LBP/sCD14 has been associated with high fat diet induced inflammation. We tested the hypothesis that healthy subjects develop inflammation differently during weight gain according to changes of LBP/sCD14 ratio. METHODS AND RESULTS Eighteen healthy men were overfed during 8 wk (+760 kcal/day). Endotoxemia, sCD14, LBP, and IL-6 were measured before and after overfeeding (OF) at fasting (n = 18) and postprandially (subcohort, n = 8). OF did not modify fasting IL-6 but increased the LBP/sCD14 ratio (P = 0.017). Subjects were categorized into tertiles for LBP/sCD14 ratio variation. Subjects in the highest tertile (+90% LBP/sCD14) increased plasma IL-6 (+26%) versus the lowest tertile due to a decrease of sCD14 associated with high LBP. The postprandial accumulation of endotoxins increased after OF (+160%). However, only four responding subjects presented increased postprandial IL-6 accumulation. CONCLUSION OF increases postprandial endotoxemia but the inflammatory outcome may be modulated by endotoxin handling in plasma. This study supports a new concept whereby inflammation setup during the initial phase of weight gain is linked to the relative variations of LBP and sCD14.
Collapse
Affiliation(s)
- Fabienne Laugerette
- CarMeN Laboratory, Université Lyon 1, Université de Lyon, Villeurbanne, France; INRA, USC1362, INSERM, U1060, CarMeN Laboratory, Villeurbanne, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis 2014; 210:234-43. [PMID: 24493824 DOI: 10.1093/infdis/jiu074] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Low 25-hydroxyvitamin D (25(OH)D) has been associated with inflammation, human immunodeficiency virus (HIV) disease progression, and death. We aimed to identify the prognostic value of 25(OH)D for AIDS, non-AIDS-defining events and death, and its association with immunological/inflammatory markers. METHODS Prospective 1-1 case-control study nested within the EuroSIDA cohort. Matched cases and controls for AIDS (n = 50 matched pairs), non-AIDS-defining (n = 63) events and death (n = 41), with plasma samples during follow-up were selected. Conditional logistic regression models investigated associations between 25(OH)D levels and annual 25(OH)D change and the probability of events. Mixed models investigated relationships between 25(OH)D levels and immunological/inflammatory markers. RESULTS In sum, 250 patients were included. Median time between first and last sample and last sample and event was 44.6(interquartile range [IQR]: 22.7-72.3) and 3.1(IQR: 1.4-6.4) months. Odds of death decreased by 46.0%(95% confidence interval [CI], 2.0-70.0, P = .04) for a 2-fold increase in latest 25(OH)D level. There was no association between 25(OH)D and the occurrence of AIDS or non-AIDS-defining events (P > .05). In patients with current 25(OH)D <10 ng/mL, hsIL-6 concentration increased by 4.7%(95% CI, .2,9.4, P = .04) annually after adjustment for immunological/inflammatory markers, and no change in hsCRP rate was observed (P = .76). CONCLUSIONS Low Vitamin D predicts short term mortality in HIV-positive persons. Effectiveness of vitamin D supplementation on inflammation and patient outcomes should be investigated.
Collapse
Affiliation(s)
- Leah Shepherd
- Department of Infection and Population Health, University College London Medical School, London, United Kingdom
| | | | - Jean-Philippe Bastard
- Department of Biochemistry, Hôpital Tenon, APHP, Paris, France INSERM, U938, Faculté de Médecine Saint Antoine, ICAN, Institute of Cardiometabolism and Nutrition, Paris, France UPMC Univ Paris 06, UMR_S 938, Paris, France
| | - Soraya Fellahi
- Department of Biochemistry, Hôpital Tenon, APHP, Paris, France INSERM, U938, Faculté de Médecine Saint Antoine, ICAN, Institute of Cardiometabolism and Nutrition, Paris, France UPMC Univ Paris 06, UMR_S 938, Paris, France
| | - Jaqueline Capeau
- Department of Biochemistry, Hôpital Tenon, APHP, Paris, France INSERM, U938, Faculté de Médecine Saint Antoine, ICAN, Institute of Cardiometabolism and Nutrition, Paris, France UPMC Univ Paris 06, UMR_S 938, Paris, France
| | - Joanne Reekie
- Department of Infection and Population Health, University College London Medical School, London, United Kingdom The Kirby Institute University of New South Wales, Sydney, New South Wales, Australia
| | - Peter Reiss
- Academic Medical Centre (AMC), University of Amsterdam, Amsterdam, the Netherlands
| | - Anders Blaxhult
- Department of Medicine, Division of Infectious Diseases, Karolinska Institute, Stockholm, Sweden
| | | | - Clifford Leen
- Edinburgh Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom Edinburgh Infectious Diseases Edinburgh University, Edinburgh, United Kingdom
| | - Ole Kirk
- Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark Department of Infectious Diseases, Centre for Viral Diseases, Rigshospitalet, Copenhagen, Denmark
| | - Jens D Lundgren
- Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark Department of Infectious Diseases, Centre for Viral Diseases, Rigshospitalet, Copenhagen, Denmark
| | - Amanda Mocroft
- Department of Infection and Population Health, University College London Medical School, London, United Kingdom
| | - Jean-Paul Viard
- Centre de Diagnostic et de Thérapeutique Hôtel-Dieu, APHP, and EA 3620, Université Paris Descartes, Paris, France
| | | |
Collapse
|